

Session text above this point is available in the transcript,
available from the **Transcript Assistant** on the toolbar.

AU Remuzzi A; Perico N; Amuchastegui C S; Malanchini B; Mazerska M; Battaglia C; Bertani T; Remuzzi G
CS Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
SO Journal of the American Society of Nephrology : JASN, (1993 Jul) 4 (1) 40-9.
Journal code: 9013836. ISSN: 1046-6673.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199310
ED Entered STN: 19940117
Last Updated on STN: 19940117
Entered Medline: 19931027

L9 ANSWER 632 OF 632 MEDLINE on STN

Full Text	References
-----------	------------

AN 92201503 MEDLINE
DN PubMed ID: 1551487
TI Renal functional reserve in the early stage of experimental **diabetes**.
AU De Nicola L; Blantz R C; Gabbai F B
CS Division of Nephrology-Hypertension, University of California, San Diego School of Medicine.
NC DK-28602 (NIDDK)
SO Diabetes, (1992 Mar) 41 (3) 267-73.
Journal code: 0372763. ISSN: 0012-1797.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199204
ED Entered STN: 19920509
Last Updated on STN: 19980206
Entered Medline: 19920427

=> d an ti au so ab kwic 625

L9 ANSWER 625 OF 632 MEDLINE on STN

Full Text	References
-----------	------------

AN 95279772 MEDLINE
TI Antihypertensive and renal-protective effects of **losartan** in streptozotocin **diabetic** rats.
AU Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Fu L P; Obara K; Saito T; Abe K
SO Journal of hypertension, (1995 Jan) 13 (1) 97-103.
Journal code: 8306882. ISSN: 0263-6352.
AB OBJECTIVE: To assess the renal benefits of a specific angiotensin II receptor antagonist, **losartan**, in **diabetic** rats with renal impairment. DESIGN AND METHODS: Uninephrectomized streptozotocin **diabetic** spontaneously hypertensive rats (SHR) were randomly assigned to receive vehicle, or to receive **losartan** or captopril, or both, intraperitoneally via osmotic minipumps for 8 weeks. RESULTS: Blood pressure and urinary protein excretion in the **diabetic** SHR increased progressively during the experimental period. Both captopril treatment and **losartan** treatment completely blocked the development of hypertension in **diabetic** SHR. Simultaneous administration of captopril and **losartan** did not enhance

the antihypertensive effects of **losartan** treatment or captopril treatment. Furthermore, **losartan** treatment, captopril treatment and **losartan** + captopril treatment all significantly decreased urinary protein excretion, urinary albumin excretion and serum creatinine to the same extent. These effects were sustained for the entire experimental period and were not associated with any significant changes in body weight, urine volume, urine sugar and urinary electrolytes excretion. These results were confirmed by morphological analysis of kidneys in each group of rats. **Losartan** treatment, captopril treatment and **losartan**+captopril treatment all significantly and effectively protected against an increase in the percentage of focal glomerular sclerosis. **Losartan** treatment and captopril treatment both significantly attenuated the increase in heart weight: body weight ratio. The heart weight: body weight ratio in the **losartan**-treated group was significantly lower than in the captopril-treated group. CONCLUSIONS: These results indicate that hypertension could accelerate **diabetic** renal impairment and that **losartan** has antihypertensive and renoprotective effects in this rat model. They also suggest that the antihypertensive and renoprotective effects of captopril treatment in this rat model are caused mainly by inhibition of angiotensin II production rather than stimulation of the kallikrein-kinin system or of vasodilator prostaglandins. The difference in potency between **losartan** treatment and captopril treatment to attenuate the increase in heart weight: body weight ratio might partly explain the existence in the heart of angiotensin-forming pathways, which are not dependent on angiotensin converting enzyme.

TI Antihypertensive and renal-protective effects of **losartan** in streptozotocin **diabetic** rats.

AB OBJECTIVE: To assess the renal benefits of a specific angiotensin II receptor antagonist, **losartan**, in **diabetic** rats with renal impairment. DESIGN AND METHODS: Uninephrectomized streptozotocin **diabetic** spontaneously hypertensive rats (SHR) were randomly assigned to receive vehicle, or to receive **losartan** or captopril, or both, intraperitoneally via osmotic minipumps for 8 weeks. RESULTS: Blood pressure and urinary protein excretion in the **diabetic** SHR increased progressively during the experimental period. Both captopril treatment and **losartan** treatment completely blocked the development of hypertension in **diabetic** SHR. Simultaneous administration of captopril and **losartan** did not enhance the antihypertensive effects of **losartan** treatment or captopril treatment. Furthermore, **losartan** treatment, captopril treatment and **losartan** + captopril treatment all significantly decreased urinary protein excretion, urinary albumin excretion and serum creatinine to the same extent. These. . . urine sugar and urinary electrolytes excretion. These results were confirmed by morphological analysis of kidneys in each group of rats. **Losartan** treatment, captopril treatment and **losartan**+captopril treatment all significantly and effectively protected against an increase in the percentage of focal glomerular sclerosis. **Losartan** treatment and captopril treatment both significantly attenuated the increase in heart weight: body weight ratio. The heart weight: body weight ratio in the **losartan**-treated group was significantly lower than in the captopril-treated group. CONCLUSIONS: These results indicate that hypertension could accelerate **diabetic** renal impairment and that **losartan** has antihypertensive and renoprotective effects in this rat model. They also suggest that the antihypertensive and renoprotective effects of captopril. . . of angiotensin II production rather than stimulation of the kallikrein-kinin system or of vasodilator prostaglandins. The difference in potency between **losartan** treatment and captopril treatment to attenuate the increase in heart weight: body weight ratio might partly explain the existence in. . .

CT . . . Check Tags: Male; Support, Non-U.S. Gov't

*Angiotensin II: AI, antagonists & inhibitors
Animals

*Biphenyl Compounds: PD, pharmacology
Captopril: PD, pharmacology

*Diabetes Mellitus, Experimental: DT, drug therapy
 Diabetes Mellitus, Experimental: ME, metabolism
 Drug Therapy, Combination
 Glomerulosclerosis, Focal: ME, metabolism
 Glomerulosclerosis, Focal: PA, pathology
 Glomerulosclerosis, Focal: PC, prevention. . . therapy
 Hypertension: ME, metabolism
 Hypertension: PA, pathology
 *Imidazoles: PD, pharmacology
 Kidney: CY, cytology
 *Kidney: DE, drug effects
 Kidney: ME, metabolism

Losartan

Organ Weight
 Random Allocation
 Rats
 Rats, Inbred SHR

*Receptors, Angiotensin: AI, antagonists & inhibitors

*Tetrazoles: PD, pharmacology

RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); 62571-86-2
 (Captopril)

=> d an ti au so ab kwic 622

L9 ANSWER 622 OF 632 MEDLINE on STN

Full Text References

AN 95360953 MEDLINE

TI A new class of therapeutic agents: the angiotensin II receptor antagonists.

AU Timmermans P B; Smith R D

SO Cardiologia (Rome, Italy), (1994 Dec) 39 (12 Suppl 1) 397-400.
 Journal code: 8506637. ISSN: 0393-1978.

AB Angiotensin II (Ang II) is the primary mediator of the renin-angiotensin system (RAS). Inappropriate control of the RAS is critically involved in the development and maintenance of hypertension and congestive heart failure. The actions of Ang II are thought to be mediated by specific surface receptors on the various target organs. At present, two receptors for Ang II have been firmly established in mammals, including man. According to current nomenclature, **losartan** represents the prototype antagonist of the Ang II type 1 (AT1) receptor and does not possess significant affinity for the so-called AT2 receptor. **Losartan** is the first of a new class of orally active, nonpeptide Ang II receptor antagonists able to very specifically and selectively inhibit the RAS while lacking the agonistic effects of the peptide receptor antagonists, e.g. saralasin, or the bradykinin potentiating effects of the angiotensin converting enzyme (ACE) inhibitors. Virtually all of the known actions of Ang II, e.g. those defined by Ang II itself, saralasin, ACE or renin-inhibitors are blocked by **losartan**, emphasizing the major role of this distinct Ang II receptor subtype in mediating the responses of Ang II. The functional correlate of the AT2 receptor remains poorly understood. In several models of experimental and genetic hypertension, AT1 receptor antagonists are effective antihypertensive agents with similar efficacy to that of ACE and renin-inhibitors. In animal models of renal disease, AT1 receptor antagonists significantly decrease proteinuria, protect against **diabetic** glomerulopathy and increase survival in stroke-prone spontaneously hypertensive rats. (ABSTRACT TRUNCATED AT 250 WORDS)

AB . . . organs. At present, two receptors for Ang II have been firmly established in mammals, including man. According to current nomenclature, **losartan** represents the prototype antagonist of the Ang II type 1 (AT1) receptor and does not possess significant affinity for the so-called AT2 receptor. **Losartan** is the first of a new class of orally active,

L1 6582 S (TELMISARTAN OR IRBESARTAN OR VALSARTAN OR LOSARTAN OR CANDES
L2 803910 S (INFLAMMATORY? OR METABOLIC OR DIABETES OR HYPERTENSION)
L3 2917 S L1 AND L2
L4 221923 S INFLAMMATOR?
L5 141 S L1 AND L4
L6 629189 S (METABOLIC OR DIABET? OR HYPERTEN?)
L7 3072 S L1 AND L6
L8 242415 S (DIABET?)
L9 632 S L1 AND L8

=> s (telmisartan or irbesartan)

252 TELMISARTAN
593 IRBESARTAN
L10 799 (TELMISARTAN OR IRBESARTAN)

=> s 18 and 110

L11 171 L8 AND L10

=> d 1-171

L11 ANSWER 1 OF 171 MEDLINE on STN

Full Text [References](#)

AN 2005019574 IN-PROCESS
DN PubMed ID: 15645839
TI [**Irbesartan** in the treatment of arterial hypertension].
Irbesartan v lecbе arterialni hypertenze.
AU Widimsky J Jr; Zizka J; Haas T
CS III. interni klinika l. LF UK, Praha.
SO Vnitřni lékařství, (2000 Jun) 46 (6) 337-40.
Journal code: 0413602. ISSN: 0042-773X.
CY Czech Republic
DT Journal; Article; (JOURNAL ARTICLE)
LA Czech
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20050114
Last Updated on STN: 20050114

L11 ANSWER 2 OF 171 MEDLINE on STN

Full Text [References](#)

AN 2004642306 IN-PROCESS
DN PubMed ID: 15617852
TI **Telmisartan** is a promising cardiometabolic sartan due to its unique
PPAR-gamma-inducing property.
AU Yamagishi S; Takeuchi M
CS Department of Medicine, Kurume University School of Medicine, Kurume,
Japan.
SO Medical hypotheses, (2005) 64 (3) 476-8.
Journal code: 7505668. ISSN: 0306-9877.
CY Scotland: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041228
Last Updated on STN: 20041228

L11 ANSWER 3 OF 171 MEDLINE on STN

Full Text [References](#)

AN 2004638171 IN-PROCESS
DN PubMed ID: 15613069
TI **Irbesartan** is projected to be cost and life saving in a Spanish setting
for treatment of patients with type 2 **diabetes**, hypertension, and

microalbuminuria.

AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lapuerta Pablo; Chen Roland; Gabriel Sylvie; Carita Paulo; Rodby Roger A; de Zeeuw Dick; Parving Hans-Henrik; De Alvaro Fernando
 CS CORE-Center for Outcomes Research, Binningen/Basel, Switzerland.
 SO Kidney international. Supplement, (2005 Jan) (93) S52-4.
 Journal code: 7508622. ISSN: 0098-6577.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041223
 Last Updated on STN: 20041223

L11 ANSWER 4 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004638166 IN-PROCESS
 DN PubMed ID: 15613064
 TI Microalbuminuria in hypertensive patients: Evaluation of one-year treatment with **irbesartan**.
 AU de Alvaro Fernando; Velasco Olga; Honorato Jesus; Calvo Carlos; Parrondo Inma
 CS Hospital Universitario La Paz, Madrid, Spain. (on Behalf of KORAL HT Investigators).
 SO Kidney international. Supplement, (2005 Jan) (93) S29-34.
 Journal code: 7508622. ISSN: 0098-6577.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041223
 Last Updated on STN: 20041223

L11 ANSWER 5 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004637797 IN-PROCESS
 DN PubMed ID: 15614015
 TI Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
 AU Kurtz Theodore W; Pravenec Michal
 CS Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA.. KurtzT@Labmed2.ucsf.edu
 NC HL63709 (NHLBI)
 TW01236 (FIC)
 SO Journal of hypertension, (2004 Dec) 22 (12) 2253-61.
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041223
 Last Updated on STN: 20041224

L11 ANSWER 6 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004616421 IN-PROCESS
 DN PubMed ID: 15592575
 TI Clinical and Experimental Aspects of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist.
 AU Yoshida Kazunori; Kohzaki Masahiro
 CS Department of Medicine, Furukawa City Hospital, Furukawa, Miyagi 989-6183, Japan.. kazunori@gakushikai.jp

SO Cardiovascular drug reviews, (2004 Winter) 22 (4) 285-308.
Journal code: 9006912. ISSN: 0897-5957.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041220
Last Updated on STN: 20041220

L11 ANSWER 7 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004607860 IN-PROCESS
DN PubMed ID: 15353911
TI Effect of **irbesartan** on the antioxidant defence system and nitric oxide release in **diabetic** rat kidney.
AU Anjaneyulu Muragundla; Chopra Kanwaljit
CS Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
SO American journal of nephrology, (2004 Sep-Oct) 24 (5) 488-96.
Journal code: 8109361. ISSN: 0250-8095.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041208
Last Updated on STN: 20041220

L11 ANSWER 8 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004574889 IN-PROCESS
DN PubMed ID: 15316606
TI Effect of **irbesartan** on nitrotyrosine generation in non-hypertensive **diabetic** patients.
AU Ceriello A; Assaloni R; Da Ros R; Maier A; Quagliaro L; Piconi L; Esposito K; Giugliano D
CS Department of Experimental and Clinical Pathology and Medicine, University of Udine, P. le S. Maria della Misericordia, 33100 Udine, Italy..
ceriello@uniud.it
SO Diabetologia, (2004 Sep) 47 (9) 1535-40.
Journal code: 0006777. ISSN: 0012-186X.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041120
Last Updated on STN: 20041220

L11 ANSWER 9 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004560107 IN-PROCESS
DN PubMed ID: 15526250
TI How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive **diabetics**.
AU Llewelyn D E Huw; Garcia-Puig Juan
CS Department of Medicine, Luton and Dunstable Hospital, Luton, Bedfordshire LU1 4OZ, UK.. HuwLlewelyn@I&d-anglox-nhs.org.uk
SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2004 Sep) 5 (3) 141-5.
Journal code: 100971636. ISSN: 1470-3203.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English

FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041110
Last Updated on STN: 20041220

L11 ANSWER 10 OF 171 MEDLINE on STN

	Full Text	Citing References
AN	2004553661	MEDLINE
DN	PubMed ID: 15516696	
TI	Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.	
CM	Comment in: N Engl J Med. 2004 Nov 4;351(19):1934-6. PubMed ID: 15516698	
AU	Barnett Anthony H; Bain Stephen C; Bouter Paul; Karlberg Bengt; Madsbad Sten; Jervell Jak; Mustonen Jukka	
CS	Division of Medical Sciences, University of Birmingham and Birmingham Heartlands and Solihull National Health Service Trust (Teaching), Birmingham, United Kingdom. (Diabetics Exposed to Telmisartan and Enalapril Study Group). anthony.barnett@heartsol.wmids.nhs.uk	
SO	New England journal of medicine, (2004 Nov 4) 351 (19) 1952-61. Journal code: 0255562. ISSN: 1533-4406.	
CY	United States	
DT	(CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) (MULTICENTER STUDY) (RANDOMIZED CONTROLLED TRIAL)	
LA	English	
FS	Abridged Index Medicus Journals; Priority Journals	
EM	200411	
ED	Entered STN: 20041105 Last Updated on STN: 20041113 Entered Medline: 20041112	

L11 ANSWER 11 OF 171 MEDLINE on STN

	Full Text	Citing References
AN	2004550348	IN-PROCESS
DN	PubMed ID: 15523550	
TI	Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.	
AU	Weinbergova Otilie; Metelka Rudolf; Vymetal Jiri; Konecny Karel; Kosatikova Zdena	
CS	Faculty of Medicine, Palacky University, Olomouc, Czech Republic.	
SO	Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, (2004 Jul) 148 (1) 69-73. Journal code: 101140142. ISSN: 1213-8118.	
CY	Czech Republic	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals	
ED	Entered STN: 20041104 Last Updated on STN: 20041220	

L11 ANSWER 12 OF 171 MEDLINE on STN

	Full Text	Citing References
AN	2004544934	IN-PROCESS
DN	PubMed ID: 15516153	
TI	Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.	
AU	Scheen Andre J	
CS	Division of Diabetes, Department of Medicine, Nutrition and Metabolic Disorders, CHU Sart Tilman, Liege, Belgium.. Andre.Scheen@chu.ulg.ac.be	
SO	Drugs, (2004) 64 (22) 2537-65. Journal code: 7600076. ISSN: 0012-6667.	
CY	New Zealand	

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041102
 Last Updated on STN: 20041220

L11 ANSWER 13 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004530677 MEDLINE
 DN PubMed ID: 15500387
 TI **Telmisartan** - killing two birds with one stone.
 AU Doggrell Sheila A
 CS School of Biomedical Sciences, University of Queensland, QLD 4072,
 Australia... s.doggrell@yahoo.com
 SO Expert opinion on pharmacotherapy, (2004 Nov) 5 (11) 2397-400. Ref: 12
 Journal code: 100897346. ISSN: 1744-7666.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200412
 ED Entered STN: 20041026
 Last Updated on STN: 20041220
 Entered Medline: 20041210

L11 ANSWER 14 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004530667 MEDLINE
 DN PubMed ID: 15500377
 TI **Telmisartan**/hydrochlorothiazide combination therapy in the treatment of
 essential hypertension.
 AU Schmieder Roland E
 CS University Erlangen-Nuremberg, Department of Medicine IV, Germany..
roland.schmieder@rzmail.uni-erlangen.de
 SO Expert opinion on pharmacotherapy, (2004 Nov) 5 (11) 2303-10. Ref: 36
 Journal code: 100897346. ISSN: 1744-7666.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200412
 ED Entered STN: 20041026
 Last Updated on STN: 20041220
 Entered Medline: 20041210

L11 ANSWER 15 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004520077 MEDLINE
 DN PubMed ID: 15490772
 TI [IRMA-pRacs: **irbesartan** in the treatment of microalbuminuria and
 proteinuria in patients with type 2 **diabetes** and hypertension-
 prospective observational study involving 38,016 patients in the general
 practice setting].
 IRMA-pRACS: **Irbesartan** zur Behandlung der Mikroalbuminurie und
 Proteinurie bei Patienten mit Typ 2 **Diabetes** und Hypertonie.
 AU Lehnert H; Bramlage P; Pittrow D; Kirch W
 CS Klinik für Endokrinologie und Stoffwechselkrankheiten der Universität
 Magdeburg.. Hendrik.Lehnert@medizin.uni-magdeburg.de
 SO MMW Fortschritte der Medizin, (2003 Oct 9) 145 Suppl 3 81-7.

Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 LA German
 FS Priority Journals
 EM 200412
 ED Entered STN: 20041020
 Last Updated on STN: 20041223
 Entered Medline: 20041222

L11 ANSWER 16 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004516495 IN-PROCESS
 DN PubMed ID: 15485429
 TI Impact of **irbesartan**, blood pressure control, and proteinuria on renal outcomes in the **Irbesartan Diabetic Nephropathy Trial**.
 AU Hunsicker Lawrence G; Atkins Robert C; Lewis Julia B; Braden Gregory; de Crespigny Paul J Champion; DeFerrari Giacomo; Drury Paul; Locatelli Francesco; Wiegmann Thomas B; Lewis Edmund J
 CS Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA. (Collaborative Study Group). lawrence-hunsicker@uiowa.edu
 SO Kidney international. Supplement, (2004 Nov) (92) S99-101.
 Journal code: 7508622. ISSN: 0098-6577.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041019
 Last Updated on STN: 20041219

L11 ANSWER 17 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004516485 IN-PROCESS
 DN PubMed ID: 15485418
 TI Predictors of cardiovascular events in patients with type 2 **diabetic nephropathy** and hypertension: a case for albuminuria.
 AU Anavekar Nagesh S; Gans Daniel J; Berl Tomas; Rohde Richard D; Cooper William; Bhaumik Amitabha; Hunsicker Lawrence G; Rouleau Jean-Lucien; Lewis Julia B; Rosendorff Clive; Porush Jerome G; Drury Paul L; Esmatjes Enric; Raz Itamar; Vanhille Phillippe; Locatelli Franceso; Goldhaber Samuel; Lewis Edmund J; Pfeffer Marc A
 CS Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.
 SO Kidney international. Supplement, (2004 Nov) (92) S50-5.
 Journal code: 7508622. ISSN: 0098-6577.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20041019
 Last Updated on STN: 20041219

L11 ANSWER 18 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004516471 IN-PROCESS
 DN PubMed ID: 15485404
 TI Health economics studies assessing **irbesartan** use in patients with hypertension, type 2 **diabetes**, and microalbuminuria.
 AU Palmer Andrew J; Rodby Roger A
 CS Center for Outcomes Research, Binningen/Basel, Switzerland..

ap@thecenter.ch

SO Kidney international. Supplement, (2004 Nov) (92) S118-20.
Journal code: 7508622. ISSN: 0098-6577.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041019
Last Updated on STN: 20041219

L11 ANSWER 19 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2004507537 MEDLINE
DN PubMed ID: 15476904
TI Comparison of the effects of **telmisartan** and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 **diabetes** mellitus and mild hypertension: a 12-month, randomized, double-blind study.
AU Derosa Giuseppe; Cicero Arrigo F G; Bertone Gianandrea; Piccinni Mario N; Fogari Elena; Ciccarelli Leonardina; Fogari Roberto
CS Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.. giuderosa@tin.it
SO Clinical therapeutics, (2004 Aug) 26 (8) 1228-36.
Journal code: 7706726. ISSN: 0149-2918.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200410
ED Entered STN: 20041013
Last Updated on STN: 20041030
Entered Medline: 20041029

L11 ANSWER 20 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2004501447 IN-PROCESS
DN PubMed ID: 15470286
TI Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.
AU Ram C Ventika S
CS Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern Medical Center, Dallas, TX, USA.. ramv@dneph.com
SO Journal of clinical hypertension (Greenwich, Conn.), (2004 Oct) 6 (10) 569-77.
Journal code: 100888554. ISSN: 1524-6175.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041008
Last Updated on STN: 20041219

L11 ANSWER 21 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2004495787 IN-PROCESS
DN PubMed ID: 15462695
TI The effect of **irbesartan** in reducing cardiovascular risk in hypertensive type 2 **diabetic** patients: an observational study in 16,600 patients in primary care.
AU Bramlage P; Pittrow D; Kirch W

CS Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus,
Technical University, Dresden, Germany.. peter.bramlage@mailbox.tu-dresden.de
SO Current medical research and opinion, (2004 Oct) 20 (10) 1625-31.
Journal code: 0351014. ISSN: 0300-7995.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20041007
Last Updated on STN: 20041219

L11 ANSWER 22 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004474802 IN-PROCESS
DN PubMed ID: 15116142
TI An economic evaluation of the **Irbesartan** in **Diabetic** Nephropathy Trial
(IDNT) in a UK setting.
AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; Bilous R W
CS Center for Outcomes Research, Basel, Switzerland.. ap@thecenter.ch
SO Journal of human hypertension, (2004 Oct) 18 (10) 733-8.
Journal code: 8811625. ISSN: 0950-9240.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20040924
Last Updated on STN: 20041219

L11 ANSWER 23 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004474796 IN-PROCESS
DN PubMed ID: 15071488
TI Effect of delapril-manidipine combination vs **irbesartan**-
hydrochlorothiazide combination on fibrinolytic function in hypertensive
patients with type II **diabetes** mellitus.
AU Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R
CS Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS
Policlinico S Matteo, University of Pavia, Pavia, Italy.
SO Journal of human hypertension, (2004 Oct) 18 (10) 687-91.
Journal code: 8811625. ISSN: 0950-9240.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20040924
Last Updated on STN: 20041219

L11 ANSWER 24 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004474051 MEDLINE
DN PubMed ID: 15384790
TI Effects of angiotensin II receptor blocker (**irbesartan**) on peritoneal
membrane functions.
AU Coronel Francisco; Berni Ana; Cigarran Secundino; Calvo Natividad; Herrero
Jose A
CS Nephrology Department, Peritoneal Dialysis Unit, Hospital Clinico San
Carlos, Madrid, Spain.. fcoronel.hcsc@salud.madrid.org
SO Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, (2004)
20 27-30.
Journal code: 9104803. ISSN: 1197-8554.
CY Canada

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200411
 ED Entered STN: 20040924
 Last Updated on STN: 20041106
 Entered Medline: 20041106

L11 ANSWER 25 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004463882 MEDLINE
 DN PubMed ID: 15353571
 TI The renal protective effects of angiotensin II receptor blockers in type 2 **diabetes** mellitus.
 CM Comment in: Ann Pharmacother. 2004 Dec;38(12):2176; author reply 2176-7.
 PubMed ID: 15599959
 AU Coyle James D; Gardner Stephanie F; White C Michael
 CS Division of Pharmacy Practice and Administration, College of Pharmacy, the Ohio State University, Columbus, OH, USA.
 SO Annals of pharmacotherapy, (2004 Oct) 38 (10) 1731-8. Ref: 31
 Journal code: 9203131. ISSN: 1060-0280.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200412
 ED Entered STN: 20040921
 Last Updated on STN: 20041223
 Entered Medline: 20041222

L11 ANSWER 26 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004463479 MEDLINE
 DN PubMed ID: 15373137
 TI [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)]. Bedroht kardiovaskuläre Risikopatienten. "Aktiviertes Renin-Angiotensin-System fordert Endorganschaden".
 AU Schunkert Heribert
 SO MMW Fortschritte der Medizin, (2004 Jun 3) 146 (23) 60.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT (INTERVIEW)
 LA German
 FS Priority Journals
 EM 200412
 ED Entered STN: 20040921
 Last Updated on STN: 20041222
 Entered Medline: 20041221

L11 ANSWER 27 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004461742 MEDLINE
 DN PubMed ID: 15369420
 TI Emerging trends for prevention and treatment of **diabetic** nephropathy: blockade of the RAAS and BP control.
 AU Hunsicker Lawrence G
 CS University of Iowa Medical School, Iowa City, USA.. lawrence-hunsicker@uiowa.edu
 SO J Manag Care Pharm, (2004 Sep) 10 (5 Suppl A) S12-7. Ref: 12

Journal code: 9605854. ISSN: 1083-4087.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200412
 ED Entered STN: 20040917
 Last Updated on STN: 20041221
 Entered Medline: 20041220

L11 ANSWER 28 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004461741 MEDLINE
 DN PubMed ID: 15369419
 TI Pharmacoeconomic challenges in the management of **diabetic** nephropathy.
 AU Rodby Roger A
 CS Rush University Medical Center, 1426 W. Washington Blvd., Chicago, IL 60607, USA.. rrodby@mindspring.com
 SO J Manag Care Pharm, (2004 Sep) 10 (5 Suppl A) S6-11.
 Journal code: 9605854. ISSN: 1083-4087.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200412
 ED Entered STN: 20040917
 Last Updated on STN: 20041221
 Entered Medline: 20041220

L11 ANSWER 29 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004398533 IN-PROCESS
 DN PubMed ID: 15302981
 TI Effects of **telmisartan** compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 **diabetic** patients: a randomized, double-blind, placebo-controlled 12-month study.
 AU Derosa Giuseppe; Ragonesi Pietro D; Mugellini Amedeo; Ciccarelli Leonardina; Fogari Roberto
 CS Department of Internal Medicine and Therapeutics, University of Pavia, Italy.. giuderosa@tin.it
 SO Hypertension research : official journal of the Japanese Society of Hypertension, (2004 Jul) 27 (7) 457-64.
 Journal code: 9307690. ISSN: 0916-9636.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20040811
 Last Updated on STN: 20041219

L11 ANSWER 30 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004380116 MEDLINE
 DN PubMed ID: 15283313
 TI [Cost-effectiveness of Ibersartan in type II **diabetic** nephropathy with hypertension. A Spanish perspective].
 Coste-efectividad de **irbesartan** en pacientes hipertensos con nefropatia **diabetica** tipo II: una perspectiva espanola.

AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; de Alvaro F
 CS Hospital La Paz, Servicio de Nefrologia, Madrid. (Grupo de Estudio Colaborativo IDNT).
 SO Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, (2004) 24 (3) 231-8.
 Journal code: 8301215. ISSN: 0211-6995.
 CY Spain
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Spanish
 FS Priority Journals
 EM 200410
 ED Entered STN: 20040801
 Last Updated on STN: 20041008
 Entered Medline: 20041007

L11 ANSWER 31 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2004372884 IN-PROCESS
 DN PubMed ID: 15277414
 TI Cost-effectiveness of early **irbesartan** treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late **irbesartan** treatment in patients with type 2 **diabetes**, hypertension, and renal disease.
 AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lamotte Mark; Lapuerta Pablo; Chen Roland; Gabriel Sylvie; Carita Paulo; Rodby Roger A; de Zeeuw Dick; Parving Hans-Henrik
 CS CORE-Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen/Basel, Switzerland.. ap@thecenter.ch
 SO Diabetes care, (2004 Aug) 27 (8) 1897-903.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20040728
 Last Updated on STN: 20041219

L11 ANSWER 32 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2004371856 MEDLINE
 DN PubMed ID: 15276098
 TI Clinically unrecognized Q-wave myocardial infarction in patients with **diabetes** mellitus, systemic hypertension, and nephropathy.
 AU Aguilar David; Goldhaber Samuel Z; Gans Daniel J; Levey Andrew S; Porush Jerome G; Lewis Julia B; Rouleau Jean-Lucien; Berl Tomas; Lewis Edmund J; Pfeffer Marc A
 CS Division of Cardiology, University of Texas Health Science Center, Houston, 77030, USA. (Collaborative Study Group).
david.aguilar@uth.tmc.edu
 SO American journal of cardiology, (2004 Aug 1) 94 (3) 337-9.
 Journal code: 0207277. ISSN: 0002-9149.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200408
 ED Entered STN: 20040728
 Last Updated on STN: 20040827
 Entered Medline: 20040826

L11 ANSWER 33 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004336962 MEDLINE
 DN PubMed ID: 15213879
 TI [Health economic aspects of the use of **irbesartan** in patients in Germany with type 2 **diabetes**, nephropathy and hypertension].
 Gesundheitsökonomische Aspekte der Anwendung von **Irbesartan** bei Patienten mit Typ-2-**Diabetes**, Nephropathie und Hypertonie in Deutschland.
 CM Comment on: Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. PubMed ID: 14703575
 AU Schute L L
 SO Deutsche medizinische Wochenschrift, (2004 Jun 18) 129 (25-26) 1448; author reply 1448.
 Journal code: 0006723. ISSN: 0012-0472.
 CY Germany: Germany, Federal Republic of
 DT Commentary
 Letter
 LA German
 FS Priority Journals
 EM 200407
 ED Entered STN: 20040709
 Last Updated on STN: 20040723
 Entered Medline: 20040722

L11 ANSWER 34 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004313076 MEDLINE
 DN PubMed ID: 15215792
 TI Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating **telmisartan**, ramipril, and their combination in high-risk patients: the Ongoing **Telmisartan** Alone and in Combination with Ramipril Global Endpoint Trial/**Telmisartan** Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
 AU Teo Koon; Yusuf Salim; Sleight Peter; Anderson Craig; Mookadam Farouk; Ramos Barbara; Hilbrich Lutz; Pogue Janice; Schumacher Helmut
 CS McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5. (ONTARGET/TRANSCEND Investigators).
 teok@mcmaster.ca
 SO American heart journal, (2004 Jul) 148 (1) 52-61.
 Journal code: 0370465. ISSN: 1097-6744.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200410
 ED Entered STN: 20040625
 Last Updated on STN: 20041006
 Entered Medline: 20041005

L11 ANSWER 35 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004262874 MEDLINE
 DN PubMed ID: 15161820
 TI Kidney function during and after withdrawal of long-term **irbesartan** treatment in patients with type 2 **diabetes** and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
 CM Comment on: Diabetes Care. 2003 Dec;26(12):3296-302. PubMed ID: 14633817
 AU Kaiser Thomas; Florack Christiane; Sawicki Peter T
 SO Diabetes care, (2004 Jun) 27 (6) 1521; author reply 1521-2.
 Journal code: 7805975. ISSN: 0149-5992.

CY United States
 DT Commentary
 Letter
 LA English
 FS Priority Journals
 EM 200501
 ED Entered STN: 20040527
 Last Updated on STN: 20050112
 Entered Medline: 20050111

L11 ANSWER 36 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004256998 MEDLINE
 DN PubMed ID: 15155118
 TI Challenges in improving prognosis and therapy: the Ongoing **Telmisartan** Alone and in Combination with Ramipril Global End point Trial programme.
 AU Zimmermann Mathias; Unger Thomas
 CS Center for Cardiovascular Research/Institute for Pharmacology and Toxicology, Charite-University Medicine Berlin, Germany.
 SO Expert opinion on pharmacotherapy, (2004 May) 5 (5) 1201-8.
 Journal code: 100897346. ISSN: 1465-6566.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200410
 ED Entered STN: 20040525
 Last Updated on STN: 20041015
 Entered Medline: 20041014

L11 ANSWER 37 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004245201 MEDLINE
 DN PubMed ID: 15101793
 TI **Irbesartan**: a review of its use in hypertension and in the management of **diabetic** nephropathy.
 AU Croom Katherine F; Curran Monique P; Goa Karen L; Perry Caroline M
 CS Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand.. demail@adis.co.nz
 SO Drugs, (2004) 64 (9) 999-1028. Ref: 148
 Journal code: 7600076. ISSN: 0012-6667.
 CY New Zealand
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200407
 ED Entered STN: 20040518
 Last Updated on STN: 20040728
 Entered Medline: 20040726

L11 ANSWER 38 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004229921 MEDLINE
 DN PubMed ID: 15007034
 TI Identification of **telmisartan** as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
 AU Benson Stephen C; Pershadsingh Harrihar A; Ho Christopher I; Chittiboyina Amar; Desai Prashant; Pravenec Michal; Qi Nianning; Wang Jiaming; Avery

Mitchell A; Kurtz Theodore W
 CS Department of Biological Sciences, California State University, Hayward, USA.
 NC 2R42AR44767-02A2 (NIAMS)
 HL63709 (NHLBI)
 TW01236 (FIC)
 SO Hypertension, (2004 May) 43 (5) 993-1002.
 Journal code: 7906255. ISSN: 1524-4563.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200410
 ED Entered STN: 20040510
 Last Updated on STN: 20041009
 Entered Medline: 20041008

L11 ANSWER 39 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004224638 MEDLINE
 DN PubMed ID: 15117841
 TI Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
 AU Schupp Michael; Janke Jurgen; Clasen Ronald; Unger Thomas; Kintscher Ulrich
 CS Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite-Mitte, Charite-Universitatsmedizin Berlin, Berlin, Germany.
 SO Circulation, (2004 May 4) 109 (17) 2054-7.
 Journal code: 0147763. ISSN: 1524-4539.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200409
 ED Entered STN: 20040505
 Last Updated on STN: 20040911
 Entered Medline: 20040910

L11 ANSWER 40 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004218897 MEDLINE
 DN PubMed ID: 15117095
 TI What is the impact of PRIME on real-life **diabetic** nephropathy?.
 AU Ruilope L M
 CS Chief Hypertension Unit, Hospital 12 de Octubre, Madrid 28041, Spain.
 SO International journal of clinical practice, (2004 Mar) 58 (3) 268-76.
 Ref: 43
 Journal code: 9712381. ISSN: 1368-5031.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200407
 ED Entered STN: 20040501
 Last Updated on STN: 20040707
 Entered Medline: 20040706

L11 ANSWER 41 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004212671 MEDLINE
 DN PubMed ID: 15109447
 TI Effect of **irbesartan** on angiotensin II-induced hypertrophy of human proximal tubular cells.
 AU Liu Bi-Cheng; Sun Jing; Chen Qi; Luo Dong-Dong; Ma Kun-Ling; Ruan Xiong-Zhong
 CS Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing 210009, China.. kidney@jlonline.com
 SO Chinese medical journal, (2004 Apr) 117 (4) 547-51.
 Journal code: 7513795. ISSN: 0366-6999.
 CY China
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200407
 ED Entered STN: 20040428
 Last Updated on STN: 20040709
 Entered Medline: 20040708

L11 ANSWER 42 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004208380 MEDLINE
 DN PubMed ID: 15047614
 TI Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.
 AU Tikellis Christos; Wookey Peter J; Candido Riccardo; Andrikopoulos Sof; Thomas Merlin C; Cooper Mark E
 CS Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.
 SO Diabetes, (2004 Apr) 53 (4) 989-97.
 Journal code: 0372763. ISSN: 0012-1797.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200405
 ED Entered STN: 20040427
 Last Updated on STN: 20040521
 Entered Medline: 20040520

L11 ANSWER 43 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004168950 MEDLINE
 DN PubMed ID: 15061687
 TI Safety of **telmisartan** in patients with arterial hypertension : an open-label observational study.
 AU Michel Martin C; Bohner Herbert; Koster Jurgen; Schafers Rafael; Heemann Uwe
 CS Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands.. m.c.michel@amc.uva.nl
 SO Drug safety : an international journal of medical toxicology and drug experience, (2004) 27 (5) 335-44.
 Journal code: 9002928. ISSN: 0114-5916.
 CY New Zealand
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200408
 ED Entered STN: 20040406
 Last Updated on STN: 20040813
 Entered Medline: 20040812

L11 ANSWER 44 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004164707 MEDLINE
 DN PubMed ID: 15030294
 TI AT1-receptor antagonism in hypertension: what has been learned with **irbesartan**?.
 AU Waeber Bernard; Burnier Michel
 CS University Hospital, Division of Pathophysiology, Lausanne, Switzerland..
 bwaeber@chuv.hospvd.ch
 SO Expert Rev Cardiovasc Ther, (2003 May) 1 (1) 23-33. Ref: 71
 Journal code: 101182328. ISSN: 1477-9072.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 20040403
 Last Updated on STN: 20040510
 Entered Medline: 20040507

L11 ANSWER 45 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004157142 MEDLINE
 DN PubMed ID: 15023892
 TI **Irbesartan** but not amlodipine suppresses **diabetes**-associated atherosclerosis.
 AU Candido Riccardo; Allen Terri J; Lassila Markus; Cao Zemin; Thallas Vicki; Cooper Mark E; Jandeleit-Dahm Karin A
 CS Vascular Division, Baker Heart Research Institute, PO Box 6492, Melbourne 8008, Victoria, Australia.
 SO Circulation, (2004 Mar 30) 109 (12) 1536-42.
 Journal code: 0147763. ISSN: 1524-4539.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200407
 ED Entered STN: 20040331
 Last Updated on STN: 20040716
 Entered Medline: 20040715

L11 ANSWER 46 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004136098 MEDLINE
 DN PubMed ID: 15029149
 TI [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
 Kandesartan - novyi blokator AT(1)-angiotenzinovykh retseptorov: osobennosti farmakologii i opyt ispol'zovaniia pri arterial'noi gipertenzii.
 AU Sidorenko B A; Preobrazhenskii D V; Soplevenko A V; Ivanova N A; Stetsenko T M
 CS Presidential Medical Center of Russia; ul. Marshala Timoshenko 15, 121356 Moscow, Russia.
 SO Kardiologiia, (2004) 44 (1) 55-65. Ref: 76
 Journal code: 0376351. ISSN: 0022-9040.
 CY Russia: Russian Federation
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)

LA Russian
FS Priority Journals
EM 200408
ED Entered STN: 20040319
Last Updated on STN: 20040806
Entered Medline: 20040805

L11 ANSWER 47 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004126091 MEDLINE
DN PubMed ID: 15017527
TI Angiotensin receptor blockers in **diabetic** nephropathy: renal and cardiovascular end points.
AU Parving Hans-Henrik; Andersen Steen; Jacobsen Peter; Christensen Per K; Rossing Kasper; Hovind Peter; Rossing Peter; Tarnow Lise
CS Steno Diabetes Center, Copenhagen, Denmark.. hparving@dadlnet.dk
SO Seminars in nephrology, (2004 Mar) 24 (2) 147-57. Ref: 70
Journal code: 8110298. ISSN: 0270-9295.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200412
ED Entered STN: 20040313
Last Updated on STN: 20041219
Entered Medline: 20041206

L11 ANSWER 48 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004111431 MEDLINE
DN PubMed ID: 15000928
TI Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in **diabetes**?.
AU Foreman Brett H; Chambliss M Lee
CS Moses Cone Health System, Greensboro, NC, USA.
SO Journal of family practice, (2004 Mar) 53 (3) 241-2. Ref: 6
Journal code: 7502590. ISSN: 0094-3509.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200404
ED Entered STN: 20040306
Last Updated on STN: 20040501
Entered Medline: 20040430

L11 ANSWER 49 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004085581 MEDLINE
DN PubMed ID: 14974331
TI [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
Gefassspatient mit hohem Infarkttrisiko. Schutzt der AT1-Blocker so gut wie ein ACE-Hemmer?.
AU Anonymous
SO MMW Fortschritte der Medizin, (2003 Dec 18) 145 (51-52) 39.
Journal code: 100893959. ISSN: 1438-3276.
CY Germany: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200404
 ED Entered STN: 20040221
 Last Updated on STN: 20040428
 Entered Medline: 20040427

L11 ANSWER 50 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004077919 MEDLINE
 DN PubMed ID: 14968145
 TI Economic evaluation of the use of **irbesartan** and amlodipine in the treatment of **diabetic** nephropathy in patients with hypertension in Canada.
 AU Coyle Douglas; Rodby Roger A
 CS Ottawa Health Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada.. dcoyle@ohri.ca
 SO Canadian journal of cardiology, (2004 Jan) 20 (1) 71-9.
 Journal code: 8510280. ISSN: 0828-282X.
 CY Canada
 DT (EVALUATION STUDIES)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200403
 ED Entered STN: 20040218
 Last Updated on STN: 20040304
 Entered Medline: 20040303

L11 ANSWER 51 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004048276 MEDLINE
 DN PubMed ID: 14749145
 TI Losartan and other angiotensin II antagonists for nephropathy in type 2 **diabetes** mellitus: a review of the clinical trial evidence.
 AU Ruilope Luis M; Segura Julian
 CS Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain..
luis.m.ruilope@teleline.es
 SO Clinical therapeutics, (2003 Dec) 25 (12) 3044-64. Ref: 86
 Journal code: 7706726. ISSN: 0149-2918.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200403
 ED Entered STN: 20040130
 Last Updated on STN: 20040319
 Entered Medline: 20040318

L11 ANSWER 52 OF 171 MEDLINE on STN

Full Text Citing References

AN 2004026407 MEDLINE
 DN PubMed ID: 14725209
 TI [New possibilities in clinical use of angiotensin II receptor inhibitors].
 Az angiotenzin II-receptor-gatlok klinikai alkalmazasanak uj lehetosegei.
 AU Matos Lajos
 CS Fovarosí Szent Janos Korház, Kardiologiai Jarobeteg-rendeles.
 SO Orvosi hetilap, (2003 Dec 7) 144 (49) 2419-23. Ref: 23
 Journal code: 0376412. ISSN: 0030-6002.

CY Hungary
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Hungarian
 FS Priority Journals
 EM 200403
 ED Entered STN: 20040117
 Last Updated on STN: 20040317
 Entered Medline: 20040316

L11 ANSWER 53 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004012072 MEDLINE
 DN PubMed ID: 14709365
 TI Clinical and nutritional correlates of C-reactive protein in type 2
diabetic nephropathy.
 AU Friedman Allon N; Hunsicker Lawrence G; Selhub Jacob; Bostom Andrew G
 CS Division of Nephrology, Indiana University School of Medicine, 1481 W.
 10th St.-111N, Indianapolis, IN 46202, USA.. allfried@iupui.edu
 NC R01 HL 67695-02 (NHLBI)
 SO Atherosclerosis, (2004 Jan) 172 (1) 121-5.
 Journal code: 0242543. ISSN: 0021-9150.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 20040108
 Last Updated on STN: 20040521
 Entered Medline: 20040520

L11 ANSWER 54 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2004006384 MEDLINE
 DN PubMed ID: 14703575
 TI [Health economic consequences of the use of **irbesartan** in patients in
 Germany with type 2 **diabetes**, nephropathy and hypertension].
 Gesundheitsökonomische Aspekte der Anwendung von **Irbesartan** bei
 Patienten mit Typ-2-**Diabetes**, Nephropathie und Hypertonie in Deutschland.
 CM Comment in: Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1448; author
 reply 1448. PubMed ID: 15213879
 AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; Ritz E
 CS Center for Outcomes Research, Basel, Schweiz.. AP@thecenter.ch
 SO Deutsche medizinische Wochenschrift, (2004 Jan 2) 129 (1-2) 13-8.
 Journal code: 0006723. ISSN: 0012-0472.
 CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200402
 ED Entered STN: 20040106
 Last Updated on STN: 20040218
 Entered Medline: 20040217

L11 ANSWER 55 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2003611423 MEDLINE
 DN PubMed ID: 14694914
 TI The **telmisartan** Programme of Research to show **Telmisartan** End-organ
 protection (PROTECTION) programme.

AU Weber Michael
 CS State University of New York Downstate College of Medicine, New York,
 USA.. michaelwebermd@cs.com
 SO Journal of hypertension, (2003 Jul) 21 Suppl 6 S37-46. Ref: 63
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200405
 ED Entered STN: 20031226
 Last Updated on STN: 20040526
 Entered Medline: 20040525

L11 ANSWER 56 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2003574421 MEDLINE
 DN PubMed ID: 14655481
 TI [Prospective treatment study of **irbesartan**. Diabetic kidneys regain
 function].
 Prospektive Versorgungsstudie zu **Irbesartan**. Diabetikernieren erholen
 sich wieder.
 AU Lehnert H; Bramlage P; Pittrow D; Kirch W
 CS Klinik fur Endokrinologie und Stoffwechselkrankheiten, Medizinische
 Fakultat, Otto-von-Guericke-Universitat, Leipziger Strasse 44, D-39120
 Magdeburg.. Hendrik.Lehnert@medizin.uni-magdeburg.de
 SO MMW Fortschritte der Medizin, (2003 Oct 9) 145 (41) 41.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200403
 ED Entered STN: 20031216
 Last Updated on STN: 20040318
 Entered Medline: 20040317

L11 ANSWER 57 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2003553881 MEDLINE
 DN PubMed ID: 14633817
 TI Kidney function during and after withdrawal of long-term **irbesartan**
 treatment in patients with type 2 **diabetes** and microalbuminuria.
 CM Comment in: Diabetes Care. 2004 Jun;27(6):1521; author reply 1521-2.
 PubMed ID: 15161820
 AU Andersen Steen; Brochner-Mortensen Jens; Parving Hans-Henrik
 CS Steno Diabetes Center, Gentofte, Denmark. (Irbesartan in Patients With
 Type 2 Diabetes and Microalbuminuria Study Group). stan@dadlnet.dk
 SO Diabetes care, (2003 Dec) 26 (12) 3296-302.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200407
 ED Entered STN: 20031125
 Last Updated on STN: 20040714
 Entered Medline: 20040713

L11 ANSWER 58 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003545686 MEDLINE
 DN PubMed ID: 14625161
 TI Recommendations for the management of special populations: renal disease in **diabetes**.
 AU Raij Leopoldo
 CS Nephrology-Hypertension Division, University of Miami School of Medicine, Nephrology-Hypertension Section, Veterans Affairs Medical Center, Miami, Florida 33125, USA.. LRaij@med.miami.edu
 SO American journal of hypertension : journal of the American Society of Hypertension, (2003 Nov) 16 (11 Pt 2) 46S-49S. Ref: 16
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200403
 ED Entered STN: 20031120
 Last Updated on STN: 20040325
 Entered Medline: 20040324

L11 ANSWER 59 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003508524 MEDLINE
 DN PubMed ID: 14586737
 TI Treatment of **diabetic** nephropathy with angiotensin II receptor antagonist.
 AU Lewis Edmund J; Lewis Julia B
 CS Rush/Presbyterian/St. Luke's Medical Center, 1426 W. Washington Blvd., Chicago, IL 60607, USA.. hfolmer@rush.edu
 SO Clinical and experimental nephrology, (2003 Mar) 7 (1) 1-8. Ref: 20
 Journal code: 9709923. ISSN: 1342-1751.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200311
 ED Entered STN: 20031031
 Last Updated on STN: 20031219
 Entered Medline: 20031126

L11 ANSWER 60 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003495602 MEDLINE
 DN PubMed ID: 14573338
 TI Role of systolic blood pressure on the progression of kidney damage in an experimental model of type 2 **diabetes** mellitus, obesity, and hypertension (Zucker rats).
 AU Gonzalez-Albarran Olga; Gomez Oscar; Ruiz Esther; Vieitez Paula; Garcia-Robles Rafael
 CS Department of Endocrinology, Hospital Ramon y Cajal, Madrid, Spain.
 SO American journal of hypertension : journal of the American Society of Hypertension, (2003 Nov) 16 (11 Pt 1) 979-85.
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)

LA English
 FS Priority Journals
 EM 200402
 ED Entered STN: 20031024
 Last Updated on STN: 20040302
 Entered Medline: 20040226

L11 ANSWER 61 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003456790 MEDLINE
 DN PubMed ID: 14518593
 TI Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation.
 AU Amano S; Yamagishi S; Inagaki Y; Okamoto T
 CS Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
 SO International journal of tissue reactions, (2003) 25 (2) 51-5.
 Journal code: 8302116. ISSN: 0250-0868.
 CY Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200404
 ED Entered STN: 20031002
 Last Updated on STN: 20040501
 Entered Medline: 20040430

L11 ANSWER 62 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003453123 MEDLINE
 DN PubMed ID: 14513950
 TI The **telmisartan** programme of research to show **Telmisartan** End-organ protection (PROTECTION) programme.
 AU Weber Michael
 CS State University of New York Downstate College of Medicine, New York, USA.. michaelwebermd@cs.com
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (2003 Jul) 21 Suppl 6 S37-46. Ref: 63
 Journal code: 8501422. ISSN: 0952-1178.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200404
 ED Entered STN: 20030930
 Last Updated on STN: 20040429
 Entered Medline: 20040428

L11 ANSWER 63 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003445129 MEDLINE
 DN PubMed ID: 12943484
 TI Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 **diabetes**.
 CM Erratum in: Expert Opin Pharmacother. 2003 Oct;4(10):1887
 AU Postma Maarten J; Kruidhof Hanneke; de Jong-van den Berg Lolkje T W; de Zeeuw Dick
 CS Groningen University Institute for Drug Exploration/University of

Groningen Research Institute of Pharmacy (GUIDE/GRIP), Department of Social Pharmacy, Pharmaco-epidemiology & Pharmacotherapy, The Netherlands.. m.postma@farm.rug.nl

SO Expert opinion on pharmacotherapy, (2003 Sep) 4 (9) 1543-50. Ref: 48
Journal code: 100897346. ISSN: 1465-6566.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200310
ED Entered STN: 20030925
Last Updated on STN: 20031015
Entered Medline: 20031014

L11 ANSWER 64 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003438759 MEDLINE
DN PubMed ID: 13679481
TI An economic evaluation of **irbesartan** in the treatment of patients with type 2 **diabetes**, hypertension and nephropathy: cost-effectiveness of **Irbesartan** in **Diabetic** Nephropathy Trial (IDNT) in the Belgian and French settings.
AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lamotte Mark; Rodby Roger A; Cordonnier Daniel J
CS Center for Outcomes Research, St Johannis-Ring 139, CH-4056 Basel, Switzerland.. ap@thecenter.ch
SO Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, (2003 Oct) 18 (10) 2059-66.
Journal code: 8706402. ISSN: 0931-0509.
CY England: United Kingdom
DT (EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200402
ED Entered STN: 20030923
Last Updated on STN: 20040207
Entered Medline: 20040206

L11 ANSWER 65 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003413122 MEDLINE
DN PubMed ID: 12951837
TI Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation.
AU Yamagishi S; Amano S; Inagaki Y; Okamoto T; Inoue H; Takeuchi M; Choei H; Sasaki N; Kikuchi S
CS Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.. shoichi@med.kurume-u.ac.jp
SO Drugs under experimental and clinical research, (2003) 29 (2) 75-80.
Journal code: 7802135. ISSN: 0378-6501.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200405
ED Entered STN: 20030904
Last Updated on STN: 20040511

Entered Medline: 20040510

L11 ANSWER 66 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003407853 MEDLINE
 DN PubMed ID: 12946554
 TI The cost-effectiveness of **irbesartan** in the treatment of hypertensive patients with type 2 **diabetic** nephropathy.
 AU Rodby Roger A; Chiou Chion Fang; Borenstein Jeff; Smitten Allison; Sengupta Nishan; Palmer Andrew J; Roze Stephane; Annemans Lieven; Simon Teresa A; Chen Roland S; Lewis Edmund J
 CS Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA. (Collaborative Study Group). rrodby@mindspring.com
 SO Clinical therapeutics, (2003 Jul) 25 (7) 2102-19.
 Journal code: 7706726. ISSN: 0149-2918.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200311
 ED Entered STN: 20030830
 Last Updated on STN: 20031218
 Entered Medline: 20031125

L11 ANSWER 67 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003376046 MEDLINE
 DN PubMed ID: 12891278
 TI [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and **diabetic** nephropathy].
 Blokator AT1-angiotenzinovykh retseptorov losartan. Chast' II. Opyt ispol'zovaniia dlia lecheniia gipertonicheskoi bolezni i **diabetcheskoi** nefropatii.
 AU Sidorenko B A; Preobrazhenskii D V; Stetsenko T M; Tarykina E V; Tsurko V V
 SO Kardiologiya, (2003) 43 (2) 88-95. Ref: 50
 Journal code: 0376351. ISSN: 0022-9040.
 CY Russia: Russian Federation
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Russian
 FS Priority Journals
 EM 200310
 ED Entered STN: 20030813
 Last Updated on STN: 20031028
 Entered Medline: 20031027

L11 ANSWER 68 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003366374 MEDLINE
 DN PubMed ID: 12899808
 TI Do **irbesartan** and amlodipine reduce cardiovascular events in **diabetic** patients?.
 CM Comment on: Ann Intern Med. 2003 Apr 1;138(7):542-9. PubMed ID: 12667024
 AU Millard Peter S
 CS Family Practice Residency Program, Eastern Maine Medical Center, Bangor, USA.. pmillard@emh.org
 SO Journal of family practice, (2003 Aug) 52 (8) 593-4.
 Journal code: 7502590. ISSN: 0094-3509.
 CY United States
 DT Commentary

Journal; Article; (JOURNAL ARTICLE)

LA English
FS PUBMED-NOT-MEDLINE
EM 200308
ED Entered STN: 20030806
Last Updated on STN: 20030830
Entered Medline: 20030829

L11 ANSWER 69 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003351910 MEDLINE
DN PubMed ID: 12882713
TI Influence of **irbesartan** on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced **diabetic** rats.
AU Liu Bi-cheng; Luo Dong-dong; Sun Jing; Ma Kun-ling; Ruan Xiong-zhong
CS Renal Division, Zhong Da Hospital, Southeast University School of Medicine, Nanjing 210009, China.
SO Zhonghua nei ke za zhi [Chinese journal of internal medicine], (2003 May) 42 (5) 320-3.
Journal code: 16210490R. ISSN: 0578-1426.
CY China
DT Journal; Article; (JOURNAL ARTICLE)
LA Chinese
FS Priority Journals
EM 200411
ED Entered STN: 20030729
Last Updated on STN: 20031218
Entered Medline: 20041119

L11 ANSWER 70 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003345777 MEDLINE
DN PubMed ID: 12877087
TI Antihypertensive therapy in renal dysfunction.
AU Ito Sadayoshi
CS Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine.
SO Nippon rinsho. Japanese journal of clinical medicine, (2003 Jul) 61 (7) 1210-8. Ref: 16
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS Priority Journals
EM 200309
ED Entered STN: 20030725
Last Updated on STN: 20030926
Entered Medline: 20030925

L11 ANSWER 71 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003315557 MEDLINE
DN PubMed ID: 12844467
TI Lessons from trials in hypertensive type 2 **diabetic** patients.
AU Ruilope Luis M
CS Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain..
luis.m.ruilope@teleline.es
SO Current hypertension reports, (2003 Aug) 5 (4) 322-8. Ref: 58
Journal code: 100888982. ISSN: 1522-6417.
CY United States

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200311
ED Entered STN: 20030708
Last Updated on STN: 20031218
Entered Medline: 20031121

L11 ANSWER 72 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003310074 MEDLINE
DN PubMed ID: 12838494
TI Outcome studies in **diabetic** nephropathy.
AU Mohanram Anupama; Toto Robert D
CS University of Texas Southwestern Medical Center Dallas, Dallas, TX
75390-8856, USA.
SO Seminars in nephrology, (2003 May) 23 (3) 255-71. Ref: 191
Journal code: 8110298. ISSN: 0270-9295.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 200310
ED Entered STN: 20030703
Last Updated on STN: 20031101
Entered Medline: 20031031

L11 ANSWER 73 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003291323 MEDLINE
DN PubMed ID: 12818479
TI Effect of **telmisartan** on the proteinuria and circadian blood pressure
profile in chronic renal patients.
AU Cupisti Adamasco; Rizza Giovanni Manca; D'Alessandro Claudia; Morelli
Ester; Barsotti Giuliano
CS Nephrology Unit, Department of Internal Medicine, University of Pisa, Via
Roma 67, 56100, Pisa, Italy.. acupisti@med.unipi.it
SO Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, (2003
May-Jun) 57 (3-4) 169-72.
Journal code: 8213295. ISSN: 0753-3322.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200402
ED Entered STN: 20030624
Last Updated on STN: 20040211
Entered Medline: 20040210

L11 ANSWER 74 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003282079 MEDLINE
DN PubMed ID: 12808810
TI [Dangerous deficits in management of hypertensive **diabetic** patients. A
kidney check is far from standard procedure].
Gefährliche Mangel bei der Versorgung von hypertensiven **Diabetikern**.
Nieren-Check noch lange nicht Standard.
AU Anonymous

SO MMW Fortschritte der Medizin, (2003 Apr 24) 145 (17) 55.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT News Announcement
 LA German
 FS Priority Journals
 EM 200310
 ED Entered STN: 20030618
 Last Updated on STN: 20031028
 Entered Medline: 20031027

L11 ANSWER 75 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003255815 MEDLINE
 DN PubMed ID: 12781906
 TI The ongoing **telmisartan** alone and in combination with ramipril global endpoint trial program.
 AU Unger Thomas
 CS Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany.. Thomas.unger@charite.de
 SO American journal of cardiology, (2003 May 22) 91 (10A) 28G-34G. Ref: 52
 Journal code: 0207277. ISSN: 0002-9149.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200307
 ED Entered STN: 20030604
 Last Updated on STN: 20030710
 Entered Medline: 20030709

L11 ANSWER 76 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003255813 MEDLINE
 DN PubMed ID: 12781904
 TI Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
 CM Comment in: Am J Cardiol. 2003 Oct 1;92(7):900. PubMed ID: 14516906
 AU Ball Stephen G; White William B
 CS Department of Cardiovascular Medicine, University of Leeds, Leeds, United Kingdom.
 SO American journal of cardiology, (2003 May 22) 91 (10A) 15G-21G. Ref: 30
 Journal code: 0207277. ISSN: 0002-9149.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200307
 ED Entered STN: 20030604
 Last Updated on STN: 20030710
 Entered Medline: 20030709

L11 ANSWER 77 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003197207 MEDLINE
 DN PubMed ID: 12716839
 TI The true overall mortality of unselected nephropathic type 2 **diabetic** patients with mild to moderate renal insufficiency.

AU Biesenbach Georg; Janko Otmar
 SO Diabetes care, (2003 May) 26 (5) 1639-40.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT Letter
 LA English
 FS Priority Journals
 EM 200312
 ED Entered STN: 20030429
 Last Updated on STN: 20031219
 Entered Medline: 20031218

L11 ANSWER 78 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003162989 MEDLINE
 DN PubMed ID: 12667050
 TI Summaries for patients. Effects of blood pressure drugs in patients with **diabetes** and kidney disease.
 CM Original report in: Ann Intern Med. 2003 Apr 1;138(7):542-9. PubMed ID: 12667024
 AU Anonymous
 SO Annals of internal medicine, (2003 Apr 1) 138 (7) 143.
 Journal code: 0372351. ISSN: 1539-3704.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (PATIENT EDUCATION HANDOUT)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200304
 ED Entered STN: 20030409
 Last Updated on STN: 20030418
 Entered Medline: 20030417

L11 ANSWER 79 OF 171 MEDLINE on STN

Full Text Citing References

AN 2003162985 MEDLINE
 DN PubMed ID: 12667024
 TI Cardiovascular outcomes in the **Irbesartan Diabetic Nephropathy Trial** of patients with type 2 **diabetes** and overt nephropathy.
 CM Comment in: J Fam Pract. 2003 Aug;52(8):593-4. PubMed ID: 12899808
 Summary for patients in: Ann Intern Med. 2003 Apr 1;138(7):143. PubMed ID: 12667050
 AU Berl Tomas; Hunsicker Lawrence G; Lewis Julia B; Pfeffer Marc A; Porush Jerome G; Rouleau Jean-Lucien; Drury Paul L; Esmatjes Enric; Hricik Donald; Parikh Chirag R; Raz Itamar; Vanhille Philippe; Wiegmann Thomas B; Wolfe Bernard M; Locatelli Francesco; Goldhaber Samuel Z; Lewis Edmund J
 CS University of Colorado Medical School, Denver, Colorado, USA. (Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group).
 SO Annals of internal medicine, (2003 Apr 1) 138 (7) 542-9.
 Journal code: 0372351. ISSN: 1539-3704.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200304
 ED Entered STN: 20030409
 Last Updated on STN: 20030418
 Entered Medline: 20030417

L11 ANSWER 80 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2003160091 MEDLINE
 DN PubMed ID: 12675866
 TI Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in **diabetic** nephropathy.
 CM Comment in: Kidney Int. 2003 Nov;64(5):1921; author reply 1921-2. PubMed ID: 14531832
 AU Jacobsen Peter; Andersen Steen; Rossing Kasper; Jensen Berit R; Parving Hans-Henrik
 CS Steno Diabetes Center, Gentofte, Denmark.. pkjacobsen@dadlnet.dk
 SO Kidney international, (2003 May) 63 (5) 1874-80.
 Journal code: 0323470. ISSN: 0085-2538.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200312
 ED Entered STN: 20030406
 Last Updated on STN: 20031218
 Entered Medline: 20031217

L11 ANSWER 81 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2003129526 MEDLINE
 DN PubMed ID: 12643209
 TI Angiotensin receptor blockers in **diabetic** nephropathy.
 AU Price D A; Hollenberg N K
 CS Department of Medicine, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.. DAprice@Partners.org
 NC 1 R01 DK54668-01 (NIDDK)
 1P50ML 53000-01
 M01RR026376 (NCRR)
 P01AC00059916
 T32 HL-07609 (NHLBI)
 SO Current diabetes reports, (2001 Dec) 1 (3) 267-74. Ref: 64
 Journal code: 101093791. ISSN: 1534-4827.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 20030320
 Last Updated on STN: 20030406
 Entered Medline: 20030404

L11 ANSWER 82 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2003097109 MEDLINE
 DN PubMed ID: 12610003
 TI Comparative effects of **Irbesartan** on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the **Irbesartan** in Patients with Type 2 **Diabetes** and Microalbuminuria study.
 AU Rossing Kasper; Christensen Per K; Andersen Steen; Hovind Peter; Hansen Henrik Post; Parving Hans-Henrik
 CS Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
 (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study).
krossing@dadlnet.dk
 SO Diabetes care, (2003 Mar) 26 (3) 569-74.

Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200309
 ED Entered STN: 20030302
 Last Updated on STN: 20030912
 Entered Medline: 20030911

L11 ANSWER 83 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003053556 MEDLINE
 DN PubMed ID: 12563568
 TI Effects of **telmisartan** on arterial stiffness in Type 2 **diabetes** patients with essential hypertension.
 AU Asmar Roland; Gosse Phillipe; Topouchian Jirar; N'tela Gilbert; Dudley Amanda; Shepherd Gillian L
 CS The Cardiovascular Institute, Paris, France.. ra@icv.org
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2002 Sep) 3 (3) 176-80.
 Journal code: 100971636. ISSN: 1470-3203.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200302
 ED Entered STN: 20030204
 Last Updated on STN: 20030222
 Entered Medline: 20030221

L11 ANSWER 84 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003043742 MEDLINE
 DN PubMed ID: 12553490
 TI Angiotensin receptor antagonists in patients with nephropathy due to type 2 **diabetes**.
 AU Eberhard Ritz; Dikow Ralf
 CS Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.. Prof.E.Ritz@t-online.de
 SO Annals of medicine, (2002) 34 (7-8) 507-13. Ref: 34
 Journal code: 8906388. ISSN: 0785-3890.
 CY Sweden
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 20030130
 Last Updated on STN: 20030429
 Entered Medline: 20030428

L11 ANSWER 85 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2003011262 MEDLINE
 DN PubMed ID: 12518183
 TI Emerging role of angiotensin II type 1 receptor blockers for the treatment

of endothelial dysfunction and vascular inflammation.

AU Mancini G B John
 CS Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada.. mancini@interchange.ubc.ca
 SO Canadian journal of cardiology, (2002 Dec) 18 (12) 1309-16. Ref: 38
 Journal code: 8510280. ISSN: 0828-282X.
 CY Canada
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 20030109
 Last Updated on STN: 20030128
 Entered Medline: 20030127

L11 ANSWER 86 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2003005538 MEDLINE
 DN PubMed ID: 12511232
 TI Mechanisms of **irbesartan** in prevention of renal lesion in streptozotocin-induced **diabetic** rats.
 AU Liu Bi-Cheng; Chen Qi; Luo Dong-Dong; Sun Jing; Phillips A O; Ruan Xiong-Zhong; Liu Nai-Feng
 CS Department of Pathophysiology, Nanjing Medical University, Nanjing 210002, China.. kidney@jlonline.com
 SO Acta pharmacologica Sinica, (2003 Jan) 24 (1) 67-73.
 Journal code: 100956087. ISSN: 1671-4083.
 CY China
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200310
 ED Entered STN: 20030105
 Last Updated on STN: 20031002
 Entered Medline: 20031001

L11 ANSWER 87 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2002741085 MEDLINE
 DN PubMed ID: 12503943
 TI Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
 AU Gardner Stephanie F; Franks Amy M
 CS Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA.. gardnerstephanief@uams.edu
 SO Annals of pharmacotherapy, (2003 Jan) 37 (1) 99-105. Ref: 29
 Journal code: 9203131. ISSN: 1060-0280.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 20021231
 Last Updated on STN: 20030425
 Entered Medline: 20030424

L11 ANSWER 88 OF 171 MEDLINE on STN

[Full Text](#) [Citing References](#)

AN 2002738413 MEDLINE

DN PubMed ID: 12501871
 TI Pharmacologic management of **diabetic** nephropathy.
 AU Vivian Eva M; Rubinstein Gail Breen
 CS University of the Sciences in Philadelphia, Philadelphia College of
 Pharmacy, Department of Pharmacy Practice and Pharmacy Administration,
 Philadelphia, Pennsylvania 19104-4495, USA.. e.vivian@usip.edu
 SO Clinical therapeutics, (2002 Nov) 24 (11) 1741-56; discussion 1719. Ref:
 57
 Journal code: 7706726. ISSN: 0149-2918.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200303
 ED Entered STN: 20021228
 Last Updated on STN: 20030401
 Entered Medline: 20030331

L11 ANSWER 89 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2002730963 MEDLINE
 DN PubMed ID: 12494060
 TI [Clinical hypertensiology: analysis of trials completed in 2001-2002].
 Klinicheskaja gipertenziologija: analiz zavershennykh issledovanii
 2001-2002 gg.
 AU Karpov Iu A
 SO Kardiologija, (2002) 42 (10) 62-6. Ref: 16
 Journal code: 0376351. ISSN: 0022-9040.
 CY Russia: Russian Federation
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Russian
 FS Priority Journals
 EM 200311
 ED Entered STN: 20021221
 Last Updated on STN: 20031104
 Entered Medline: 20031103

L11 ANSWER 90 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2002705701 MEDLINE
 DN PubMed ID: 12467154
 TI [The effect of angiotensin-converting enzyme inhibitors on the progression
 of chronic renal failure].
 Action des inhibiteurs de l'enzyme de conversion sur l'evolution de
 l'insuffisance renale chronique.
 AU Bernadet-Monrozies Pauline; Rostaing Lionel; Kamar Nassim; Durand
 Dominique
 CS Service de nephrologie, hypertension arterielle, dialyse et
 transplantation, Hopital Rangueil, 31403 Toulouse.
 SO Presse medicale (Paris, France : 1983), (2002 Nov 9) 31 (36) 1714-20.
 Ref: 49
 Journal code: 8302490. ISSN: 0755-4982.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA French
 FS Priority Journals
 EM 200212

ED Entered STN: 20021217
Last Updated on STN: 20021227
Entered Medline: 20021223

L11 ANSWER 91 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002705069 MEDLINE
DN PubMed ID: 12466318
TI Renal and cardiovascular protection in type 2 **diabetes** mellitus:
angiotensin II receptor blockers.
AU Deferrari Giacomo; Ravera Maura; Deferrari Luca; Vettoretti Simone; Ratto
Elena; Parodi Denise
CS Department of Internal Medicine, Section of Nephrology and Dialysis,
University of Genoa, Genoa, Italy.. gildaplm@unige.it
SO Journal of the American Society of Nephrology : JASN, (2002 Nov) 13 Suppl
3 S224-9. Ref: 53
Journal code: 9013836. ISSN: 1046-6673.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200304
ED Entered STN: 20021217
Last Updated on STN: 20030417
Entered Medline: 20030415

L11 ANSWER 92 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002670490 MEDLINE
DN PubMed ID: 12430248
TI Evidence for the benefits of ACE inhibitors and AII antagonists in slowing
progressive renal failure in **diabetes**.
AU Suzuki Hiromichi
CS Department of Nephrology, Saitama Medical School.
SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl
10 323-8. Ref: 12
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS Priority Journals
EM 200302
ED Entered STN: 20021115
Last Updated on STN: 20030221
Entered Medline: 20030220

L11 ANSWER 93 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002670486 MEDLINE
DN PubMed ID: 12430244
TI Evidence based treatment of **diabetic** nephropathy.
AU Sugimoto Toshiro
CS Third Department of Medicine, Shiga University of Medical Science.
SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl
10 294-300. Ref: 24
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA Japanese
FS Priority Journals
EM 200302
ED Entered STN: 20021115
Last Updated on STN: 20030221
Entered Medline: 20030220

L11 ANSWER 94 OF 171 MEDLINE on STN

Full Text Citing
References

AN 2002670481 MEDLINE
DN PubMed ID: 12430239
TI **Diabetic** nephropathy.
AU Haneda Masakazu
CS Third Department of Medicine, Shiga University of Medical Science.
SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl
10 260-9. Ref: 23
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS Priority Journals
EM 200302
ED Entered STN: 20021115
Last Updated on STN: 20030221
Entered Medline: 20030220

L11 ANSWER 95 OF 171 MEDLINE on STN

Full Text Citing
References

AN 2002658246 MEDLINE
DN PubMed ID: 12401753
TI Proteinuria as a predictor of total plasma homocysteine levels in type 2
diabetic nephropathy.
AU Friedman Allon N; Hunsicker Lawrence G; Selhub Jacob; Bostom Andrew G
CS Vitamin Metabolism and Aging, Jean Mayer United States Department of
Agriculture Human Nutrition Research Center on Aging, Tufts University,
Boston, Massachusetts 02111, USA. (Collaborative Study Group).
fried9572@pacl.com
NC R01 HL 67695-02 (NHLBI)
SO Diabetes care, (2002 Nov) 25 (11) 2037-41.
Journal code: 7805975. ISSN: 0149-5992.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200304
ED Entered STN: 20021107
Last Updated on STN: 20030418
Entered Medline: 20030417

L11 ANSWER 96 OF 171 MEDLINE on STN

Full Text Citing
References

AN 2002653107 IN-PROCESS
DN PubMed ID: 12410857
TI Angiotensin blockade in type 2 **diabetic** renal disease.
AU Ruilope Luis Miguel; Luno Jose
CS Unidad de Hipertension, Hospital 12 de Octubre, and Servicio de
Nefrologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain.
SO Kidney international. Supplement, (2002 Dec) (82) 61-3.

Journal code: 7508622. ISSN: 0098-6577.

CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20021105
 Last Updated on STN: 20021211

L11 ANSWER 97 OF 171 MEDLINE on STN

Full Text ☐ Citing References ☐

AN 2002652897 MEDLINE
 DN PubMed ID: 12411451
 TI Angiotensin blockade prevents type 2 **diabetes** by formation of fat cells.
 AU Sharma Arya M; Janke Jurgen; Gorzelniak Kerstin; Engeli Stefan; Luft Friedrich C
 CS HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite, Humboldt University of Berlin, and Max Delbrück Center for Molecular Medicine, Berlin, Germany.. sharma@ccc.mcmaster.ca
 SO Hypertension, (2002 Nov) 40 (5) 609-11.
 Journal code: 7906255. ISSN: 1524-4563.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200211
 ED Entered STN: 20021105
 Last Updated on STN: 20021211
 Entered Medline: 20021108

L11 ANSWER 98 OF 171 MEDLINE on STN

Full Text ☐ Citing References ☐

AN 2002650227 MEDLINE
 DN PubMed ID: 12409940
 TI Antihypertensive treatment in patients with type-2 **diabetes** mellitus: what guidance from recent controlled randomized trials?..
 AU Zanchetti Alberto; Ruilope Luis M
 CS Centro di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore and Istituto Auxologico Italiano, Milano, Italy.. zanchetti@mailserver.unimi.it
 SO Journal of hypertension, (2002 Nov) 20 (11) 2099-110. Ref: 55
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA English
 FS Priority Journals
 EM 200305
 ED Entered STN: 20021105
 Last Updated on STN: 20030530
 Entered Medline: 20030529

L11 ANSWER 99 OF 171 MEDLINE on STN

Full Text ☐ Citing References ☐

AN 2002643663 MEDLINE
 DN PubMed ID: 12402931
 TI EC approves **irbesartan** for the treatment of **diabetic** renal disease.
 AU Anonymous
 SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2002 Jul-Aug) 13 (4) 216-7.
 Journal code: 100964061. ISSN: 1015-9657.

CY South Africa
 DT News Announcement
 LA English
 FS Priority Journals
 EM 200212
 ED Entered STN: 20021030
 Last Updated on STN: 20021218
 Entered Medline: 20021213

L11 ANSWER 100 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002642476 MEDLINE
 DN PubMed ID: 12401731
 TI **Irbesartan** reduces the albumin excretion rate in microalbuminuric type 2 **diabetic** patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
 AU Sasso Ferdinando C; Carbonara Ornella; Persico Marcello; Iafusco Dario; Salvatore Teresa; D'Ambrosio Rosanna; Torella Roberto; Cozzolino Domenico
 CS Internal Medicine Unit, Second University of Naples, Naples, Italy. Pediatrics Unit, Second University of Naples, Naples, Italy.. ferdinando.sasso@unima2.it
 SO Diabetes care, (2002 Nov) 25 (11) 1909-13.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 20021029
 Last Updated on STN: 20030418
 Entered Medline: 20030417

L11 ANSWER 101 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002639612 MEDLINE
 DN PubMed ID: 12398574
 TI Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.
 AU Kalus James S; White C Michael
 CS Hartford Hospital/University of Connecticut; Hartford, CT, USA.
 SO Annals of pharmacotherapy, (2002 Nov) 36 (11) 1759-66. Ref: 47
 Journal code: 9203131. ISSN: 1060-0280.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English
 FS Priority Journals
 EM 200302
 ED Entered STN: 20021026
 Last Updated on STN: 20030222
 Entered Medline: 20030221

L11 ANSWER 102 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002638906 MEDLINE
 DN PubMed ID: 12397704
 TI Large scale clinical trials in prevention of end-stage renal disease due to type 2 **diabetes** with angiotensin receptor antagonists.
 AU Suzuki Hiromichi

CS Department of Nephrology, Saitama Medical School.
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 (10)
 2040-4. Ref: 5
 Journal code: 0420546. ISSN: 0047-1852.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA Japanese
 FS Priority Journals
 EM 200212
 ED Entered STN: 20021026
 Last Updated on STN: 20021219
 Entered Medline: 20021218

L11 ANSWER 103 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002629891 MEDLINE
 DN PubMed ID: 12387069
 TI What is a good marker for better antihypertensive therapy in **diabetic**
 patients when coexisting with hypertension.
 AU Eguchi Kazuo; Kario Kazuomi; Shimada Kazuyuki
 CS Department of Internal Medicine, Nishiarita Kyoritsu Hospital.
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Sep) 60 Suppl
 9 679-84. Ref: 29
 Journal code: 0420546. ISSN: 0047-1852.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Japanese
 FS Priority Journals
 EM 200212
 ED Entered STN: 20021022
 Last Updated on STN: 20021227
 Entered Medline: 20021224

L11 ANSWER 104 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002625743 MEDLINE
 DN PubMed ID: 12383593
 TI The role of angiotensin II receptor blockers in preventing the progression
 of renal disease in patients with type 2 **diabetes**.
 AU Lewis Edmund J
 CS Department of Nephrology, Rush-Presbyterian-St. Luke's Medical Center,
 Chicago, Illinois 60612, USA.
 SO American journal of hypertension : journal of the American Society of
 Hypertension, (2002 Oct) 15 (10 Pt 2) 123S-128S. Ref: 24
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA English
 FS Priority Journals
 EM 200303
 ED Entered STN: 20021018
 Last Updated on STN: 20030304
 Entered Medline: 20030303

L11 ANSWER 105 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002497805 MEDLINE
 DN PubMed ID: 12358875
 TI Type 2 **diabetes**, obesity, and the renal response to blocking the renin system with **irbesartan**.
 AU Price D A; Lansang M C; Osei S Y; Fisher N D L; Laffel L M B; Hollenberg N K
 CS Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.. DAPrice@Partners.org
 NC 1K23K0281601 (NCRR)
 1P50ML 5300001
 M01RR026376 (NIDDK)
 P01AC00059916 (NHLBI)
 R01 DK54668-01
 T32 HL-07609
 SO Diabetic medicine : a journal of the British Diabetic Association, (2002 Oct) 19 (10) 858-61.
 Journal code: 8500858. ISSN: 0742-3071.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 20021003
 Last Updated on STN: 20030124
 Entered Medline: 20030123

L11 ANSWER 106 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2002463816 MEDLINE
 DN PubMed ID: 12222627
 TI Evolving therapeutic strategies for retarding progression of **diabetic** nephropathy--an update for 2002.
 AU Epstein M
 CS Nephrology Section, VA Medical Center, Miami, FL 33125, USA.
 SO Acta diabetologica, (2002 Jun) 39 Suppl 2 S41-5. Ref: 21
 Journal code: 9200299. ISSN: 0940-5429.
 CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200303
 ED Entered STN: 20020912
 Last Updated on STN: 20030327
 Entered Medline: 20030326

L11 ANSWER 107 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2002427796 MEDLINE
 DN PubMed ID: 12184030
 TI [**Irbesartan**--antihypertensive treatment in patients with heart failure and **diabetes** mellitus].
Irbesartan w terapii nadciśnienia tętniczego u chorych z niewydolnością krążenia i cukrzycą.
 AU Zukowska-Szczechowska Ewa; Gosek Katarzyna; Grzeszczak Władysław
 CS Klinika Chorób Wewnętrznych i Diabetologii, Śląskiej Akademii Medycznej w Zabrze.
 SO Przegląd lekarski, (2002) 59 (3) 160-4. Ref: 52
 Journal code: 19840720R. ISSN: 0033-2240.
 CY Poland
 DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA Polish
FS Priority Journals
EM 200210
ED Entered STN: 20020820
Last Updated on STN: 20021031
Entered Medline: 20021030

L11 ANSWER 108 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002425841 MEDLINE
DN PubMed ID: 12182249
TI The role of angiotensin II antagonism in type 2 **diabetes** mellitus: a review of renoprotection studies.
AU Zanella Maria-Teresa; Ribeiro Artur B
CS Division of Nephrology, Hospital do Rim e Hipertensao, Federal University of Sao Paulo, Sao Paulo, Brazil.. tereza.zanella@hrim.com.br
SO Clinical therapeutics; (2002 Jul) 24 (7) 1019-34. Ref: 76
Journal code: 7706726. ISSN: 0149-2918.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200303
ED Entered STN: 20020817
Last Updated on STN: 20030311
Entered Medline: 20030310

L11 ANSWER 109 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002418229 MEDLINE
DN PubMed ID: 12172324
TI Renal expression of angiotensin receptors in long-term **diabetes** and the effects of angiotensin type 1 receptor blockade.
AU Bonnet Fabrice; Candido Riccardo; Carey Robert M; Casley David; Russo Leileata M; Osicka Tanya M; Cooper Mark E; Cao Zemin
CS Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Victoria 3081, Australia.
SO Journal of hypertension; (2002 Aug) 20 (8) 1615-24.
Journal code: 8306882. ISSN: 0263-6352.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 20020813
Last Updated on STN: 20030207
Entered Medline: 20030206

L11 ANSWER 110 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002386325 MEDLINE
DN PubMed ID: 12134723
TI [ACE inhibitor or AT1 antagonist. Is there a differential therapy?]. ACE-Hemmer oder AT1-Antagonist. Gibt es eine Differenzialtherapie?.
AU Unger Th; Rangoonwala B; Rosenthal J
CS Institut fur Pharmakologie und Toxikologie, Universitätsklinikum Charite der Humboldt Universität, Berlin.. thomas.unger@charite.de
SO MMW Fortschritte der Medizin; (2002 Jun 13) 144 (24) 36-8.

Journal code: 100893959. ISSN: 1438-3276.

CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200210
 ED Entered STN: 20020724
 Last Updated on STN: 20021002
 Entered Medline: 20021001

L11 ANSWER 111 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002375011 MEDLINE
 DN PubMed ID: 12121010
 TI Recent landmark clinical trials: how do they modify the therapeutic paradigm?
 AU Epstein Murray
 CS Department of Medicine, University of Miami School of Medicine, Florida 33125, USA.. murraye@gate.net
 SO American journal of hypertension : journal of the American Society of Hypertension, (2002 Jul) 15 (7 Pt 2) 82S-84S. Ref: 13
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW LITERATURE)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 20020718
 Last Updated on STN: 20030111
 Entered Medline: 20030110

L11 ANSWER 112 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002303473 MEDLINE
 DN PubMed ID: 12045787
 TI Angiotensin blockade in type 2 **diabetes**: what the new evidence tells us about renal and cardiac complications.
 AU Studney Donald
 CS University of British Columbia, Vancouver, Canada..
 studney@interchange.ubc.ca
 SO Canadian journal of cardiology, (2002 May) 18 Suppl A 3A-6A. Ref: 11
 Journal code: 8510280. ISSN: 0828-282X.
 CY Canada
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200206
 ED Entered STN: 20020605
 Last Updated on STN: 20020626
 Entered Medline: 20020625

L11 ANSWER 113 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002292224 MEDLINE
 DN PubMed ID: 12032191
 TI Dual blockade of the renin-angiotensin system in type 1 patients with **diabetic** nephropathy.
 AU Jacobsen Peter; Andersen Steen; Rossing Kasper; Hansen Birgitte V; Parving

Hans-Henrik
 CS Steno Diabetes Center, Gentofte, Denmark.. pkjacobsen@dadlnet.dk
 SO Nephrology, dialysis, transplantation : official publication of the
 European Dialysis and Transplant Association - European Renal Association,
 (2002 Jun) 17 (6) 1019-24.
 Journal code: 8706402. ISSN: 0931-0509.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200301
 ED Entered STN: 20020529
 Last Updated on STN: 20030111
 Entered Medline: 20030110

L11 ANSWER 114 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002274881 MEDLINE
 DN PubMed ID: 12015188
 TI Rationale and design of **diabetics** exposed to **telmisartan** and enalapril
 (DETAIL) study.
 AU Rippin J; Bain S C; Barnett A H
 CS Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK.
 (DETAIL study).
 SO Journal of diabetes and its complications, (2002 May-Jun) 16 (3) 195-200.
 Journal code: 9204583. ISSN: 1056-8727.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200210
 ED Entered STN: 20020517
 Last Updated on STN: 20021008
 Entered Medline: 20021004

L11 ANSWER 115 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002257703 MEDLINE
 DN PubMed ID: 11996640
 TI Class benefits of AT(1) antagonists in Type 2 **diabetes** with nephropathy.
 AU Doggrell Sheila A
 CS Department of Physiology and Pharmacology, School of Biomedical Sciences,
 University of Queensland, 4072 Australia.. s_doggrell@yahoo.com
 SO Expert opinion on pharmacotherapy, (2002 May) 3 (5) 625-8.
 Journal code: 100897346. ISSN: 1465-6566.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200209
 ED Entered STN: 20020509
 Last Updated on STN: 20020906
 Entered Medline: 20020905

L11 ANSWER 116 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002255828 MEDLINE

DN PubMed ID: 11996197
 TI Current recommendations for the treatment of hypertension: are they still valid?..
 AU Moser Marvin
 CS Yale University School of Medicine, Scarsdale, New York 10583, USA..
 Moser@aol.com
 SO Journal of hypertension, (2002 Feb) 20 Suppl 1 S3-10.
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT Editorial
 LA English
 FS Priority Journals
 EM 200209
 ED Entered STN: 20020509
 Last Updated on STN: 20020912
 Entered Medline: 20020911

L11 ANSWER 117 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002246981 MEDLINE
 DN PubMed ID: 11985424
 TI **Irbesartan** reduced progression of nephropathy caused by type 2 **diabetes** independent of the effect on blood pressure.
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517
 AU Rabbat Christian G
 CS McMaster University, Hamilton, Ontario, Canada.
 SO ACP journal club, (2002 May-Jun) 136 (3) 82-4.
 Journal code: 9104824. ISSN: 1056-8751.
 CY United States
 DT Commentary
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS PUBMED-NOT-MEDLINE
 EM 200205
 ED Entered STN: 20020503
 Last Updated on STN: 20020528
 Entered Medline: 20020523

L11 ANSWER 118 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002246980 MEDLINE
 DN PubMed ID: 11985423
 TI **Irbesartan** was renoprotective in patients with type 2 **diabetes**, hypertension, and microalbuminuria.
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519
 AU Rabbat Christian G
 CS McMaster University, Hamilton, Ontario, Canada.
 SO ACP journal club, (2002 May-Jun) 136 (3) 82-4.
 Journal code: 9104824. ISSN: 1056-8751.
 CY United States
 DT Commentary
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS PUBMED-NOT-MEDLINE
 EM 200205
 ED Entered STN: 20020503
 Last Updated on STN: 20020528
 Entered Medline: 20020523

L11 ANSWER 119 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002246309 MEDLINE

DN PubMed ID: 11986904
 TI Angiotensin II receptor antagonists role in arterial hypertension.
 AU Hernandez-Hernandez R; Sosa-Canache B; Velasco M; Armas-Hernandez M J;
 Armas-Padilla M C; Cammarata R
 CS Clinical Pharmacology Unit, Center of Biomedical Research, School of
 Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto,
 Venezuela.. rhernan@cantv.net
 SO Journal of human hypertension, (2002 Mar) 16 Suppl 1 S93-9. Ref: 59
 Journal code: 8811625. ISSN: 0950-9240.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200207
 ED Entered STN: 20020503
 Last Updated on STN: 20020724
 Entered Medline: 20020723

L11 ANSWER 120 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002178953 MEDLINE
 DN PubMed ID: 11910830
 TI [Diabetic patient with hypertension takes A-I I blocker. Less likely
 dialysis].
Diabetiker mit Hochdruck nimmt A-II-Blocker. Seltener zur Dialyse.
 AU Anonymous
 SO MMW Fortschritte der Medizin, (2002 Feb 21) 144 (8) 52.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200204
 ED Entered STN: 20020326
 Last Updated on STN: 20020420
 Entered Medline: 20020419

L11 ANSWER 121 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002170289 MEDLINE
 DN PubMed ID: 11901904
 TI [The best of 2001. Arterial hypertension].
 L'essentiel de 2001 sur l'hypertension arterielle.
 AU Laurent S
 CS Service de pharmacologie, INSERM EMI 107, Hopital europeen
 Georges-Pompidou, 20, rue Leblanc, 75015 Paris.
 SO Archives des maladies du coeur et des vaisseaux, (2002 Jan) 95 Spec No 1
 (5 Spec 1) 9-12. Ref: 12
 Journal code: 0406011. ISSN: 0003-9683.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA French
 FS Priority Journals
 EM 200210
 ED Entered STN: 20020321
 Last Updated on STN: 20021010
 Entered Medline: 20021008

L11 ANSWER 122 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002146932 MEDLINE
 DN PubMed ID: 11881102
 TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes** mellitus.
 AU Asmar R
 CS L'Institut CardioVasculaire, Paris, 75016, France.. ra@icv.org
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 Suppl 2 S8-11.
 Journal code: 100971636. ISSN: 1470-3203.
 CY England: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200208
 ED Entered STN: 20020307
 Last Updated on STN: 20020813
 Entered Medline: 20020812

L11 ANSWER 123 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002144432 MEDLINE
 DN PubMed ID: 11873779
 TI Angiotensin-receptor blockers, type 2 **diabetes**, and renoprotection.
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517
 Comment on: N Engl J Med. 2001 Sep 20;345(12):861-9. PubMed ID: 11565518
 Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519
 AU Ceriello Antonio; Motz Enrico
 SO New England journal of medicine, (2002 Feb 28) 346 (9) 705-7.
 Journal code: 0255562. ISSN: 1533-4406.
 CY United States
 DT Commentary
 Letter
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200203
 ED Entered STN: 20020307
 Last Updated on STN: 20020307
 Entered Medline: 20020306

L11 ANSWER 124 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002144431 MEDLINE
 DN PubMed ID: 11873778
 TI Angiotensin-receptor blockers, type 2 **diabetes**, and renoprotection.
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517
 Comment on: N Engl J Med. 2001 Sep 20;345(12):861-9. PubMed ID: 11565518
 Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519
 AU Walser Mackenzie
 SO New England journal of medicine, (2002 Feb 28) 346 (9) 705-7.
 Journal code: 0255562. ISSN: 1533-4406.
 CY United States
 DT Commentary
 Letter
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200203
 ED Entered STN: 20020307

Last Updated on STN: 20020307
Entered Medline: 20020306

L11 ANSWER 125 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002143947 MEDLINE
DN PubMed ID: 11881118
TI Renoprotection in Type 2 **diabetes**: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
AU Swift P A; MacGregor G A
SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 (3) 170-3. Ref: 27
Journal code: 100971636. ISSN: 1470-3203.
CY England: United Kingdom
DT Editorial
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020307
Last Updated on STN: 20020424
Entered Medline: 20020423

L11 ANSWER 126 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002143918 MEDLINE
DN PubMed ID: 11881063
TI Comparative antihypertensive and renoprotective effects of **telmisartan** and lisinopril after long-term treatment in hypertensive **diabetic** rats.
AU Wienen W; Richard S; Champeroux P; Audeval-Gerard C
CS Department of Pharma Research, Boehringer Ingelheim, Pharma KG, Biberach, Germany.. wolfgang.wienen@bc.boehringer-ingelheim.com
SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Mar) 2 (1) 31-6.
Journal code: 100971636. ISSN: 1470-3203.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020307
Last Updated on STN: 20020424
Entered Medline: 20020423

L11 ANSWER 127 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002136221 MEDLINE
DN PubMed ID: 11871182
TI [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
Angiotensin-2-receptorblockare: hur forklarar vi den njurskyddande effekten?
AU Arner Peter
CS Centrum for metabolism och endokrinologi, Huddinge Universitetssjukhus, Stockholm.. peter.arner@medhs.ki.se
SO Lakartidningen, (2002 Jan 10) 99 (1-2) 80-2.
Journal code: 0027707. ISSN: 0023-7205.
CY Sweden
DT Journal; Article; (JOURNAL ARTICLE)
LA Swedish
FS Priority Journals

EM 200203
ED Entered STN: 20020302
Last Updated on STN: 20020403
Entered Medline: 20020327

L11 ANSWER 128 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002104848 MEDLINE
DN PubMed ID: 11835907
TI From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
AU Yusuf Salim
CS Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. yusufs@mcmaster.ca
SO American journal of cardiology, (2002 Jan 24) 89 (2A) 18A-25A; discussion 25A-26A.
Journal code: 0207277. ISSN: 0002-9149.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(META-ANALYSIS)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200202
ED Entered STN: 20020212
Last Updated on STN: 20020223
Entered Medline: 20020222

L11 ANSWER 129 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002098783 MEDLINE
DN PubMed ID: 11828609
TI Preventing nephropathy in patients with type 2 **diabetes**.
AU Anonymous
SO Managed care interface, (2002 Jan) 15 (1) 72-5.
Journal code: 9715194. ISSN: 1096-5645.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Health
EM 200202
ED Entered STN: 20020207
Last Updated on STN: 20020228
Entered Medline: 20020227

L11 ANSWER 130 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002096064 MEDLINE
DN PubMed ID: 11825317
TI Angiotensin II receptor blockers for the treatment of hypertension.
AU See S
CS St. John's University College of Pharmacy, 8000 Utopia Parkway, NY 11439, USA.. sees@stjohns.edu
SO Expert opinion on pharmacotherapy, (2001 Nov) 2 (11) 1795-804. Ref: 52
Journal code: 100897346. ISSN: 1465-6566.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200209
ED Entered STN: 20020205

Last Updated on STN: 20020927
Entered Medline: 20020926

L11 ANSWER 131 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002092327 MEDLINE
DN PubMed ID: 11821641
TI Type 2 **diabetes**: RENAAL and IDNT--the emergence of new treatment options.
AU Sica Domenic A; Bakris George L
CS Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-1060, USA.. dsica@hsc.vcu.edu
SO Journal of clinical hypertension (Greenwich, Conn.), (2002 Jan-Feb) 4 (1) 52-7.
Journal code: 100888554. ISSN: 1524-6175.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200203
ED Entered STN: 20020201
Last Updated on STN: 20020319
Entered Medline: 20020318

L11 ANSWER 132 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002065095 MEDLINE
DN PubMed ID: 11791035
TI Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
AU Ferrari Paolo; Marti Hans-Peter; Pfister Marc; Frey Felix J
CS Division of Nephrology and Hypertension, Inselspital, University of Berne, Freiburgstrasse 10, 3010 Berne, Switzerland.. paolo.ferrari@insel.ch
SO Journal of hypertension, (2002 Jan) 20 (1) 125-30.
Journal code: 8306882. ISSN: 0263-6352.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020125
Last Updated on STN: 20020412
Entered Medline: 20020410

L11 ANSWER 133 OF 171 MEDLINE on STN

Full Text Citing References

AN 2002051143 MEDLINE
DN PubMed ID: 11773985
TI The protective effect of blocking angiotensin in both type I and type II **diabetics** with nephropathy.
AU Beevers D G; Lip G Y
CS University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.. g.y.h.lip@bham.ac.uk
SO Journal of human hypertension, (2001 Dec) 15 (12) 837-9. Ref: 14
Journal code: 8811625. ISSN: 0950-9240.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200202

ED Entered STN: 20020125
Last Updated on STN: 20020206
Entered Medline: 20020205

L11 ANSWER 134 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2002038112 MEDLINE
DN PubMed ID: 11765585
TI [Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 **diabetes**: results of the IDNT and RENAAL trials].
Etude clinique du mois. Role nephroprotecteur des antagonistes du recepteur de l'angiotensine II (ARA) dans le **diabete** de type 2: resultats des etudes IDNT et RENAAL.
AU Weekers L; Krzesinski J M
CS Service de Nephrologie, CHU Sart-Tilman.
SO Revue medicale de Liege, (2001 Oct) 56 (10) 723-6.
Journal code: 0404317. ISSN: 0370-629X.
CY Belgium
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 200201
ED Entered STN: 20020124
Last Updated on STN: 20020125
Entered Medline: 20020104

L11 ANSWER 135 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2002030224 MEDLINE
DN PubMed ID: 11766619
TI **Irbesartan** slows the development of **diabetic** nephropathy by up to 70% in hypertensive **diabetic** patients.
AU Anonymous
SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2001 Aug-Sep) 12 (4) 242-3.
Journal code: 100964061. ISSN: 1015-9657.
CY South Africa
DT News Announcement
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20020124
Last Updated on STN: 20020125
Entered Medline: 20020110

L11 ANSWER 136 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2002030222 MEDLINE
DN PubMed ID: 11766617
TI **Irbesartan** prevents the progression of kidney disease or death in patients with type 2 **diabetes** and high blood pressure.
AU Anonymous
SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2001 Aug-Sep) 12 (4) 240-1.
Journal code: 100964061. ISSN: 1015-9657.
CY South Africa
DT News Announcement
LA English

FS Priority Journals
EM 200201
ED Entered STN: 20020124
Last Updated on STN: 20020125
Entered Medline: 20020110

L11 ANSWER 137 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002024119 MEDLINE
DN PubMed ID: 11465914
TI Hypertension and **diabetes**: the scope of the problem.
AU Parving H H
CS Steno Diabetes Center, Gentofte, Denmark.
SO Blood pressure. Supplement, (2001) 2 25-31. Ref: 39
Journal code: 9300787. ISSN: 0803-8023.
CY Norway
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20020121
Last Updated on STN: 20020125
Entered Medline: 20020110

L11 ANSWER 138 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2002008949 MEDLINE
DN PubMed ID: 11333010
TI The role of angiotensin II receptor antagonists in the management of **diabetes**.
AU Barnett A H
CS Birmingham Heartlands Hospital, Department of Medicine, UK.
SO Blood pressure. Supplement, (2001) 1 21-6. Ref: 41
Journal code: 9300787. ISSN: 0803-8023.
CY Norway
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20020121
Last Updated on STN: 20020125
Entered Medline: 20020108

L11 ANSWER 139 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001648685 MEDLINE
DN PubMed ID: 11700829
TI Renal protection by angiotensin II receptor antagonists in patients with type 2 **diabetes**.
CM Comment in: Med J Aust. 2002 Mar 18;176(6):296-7; author reply 297. PubMed ID: 11999268
AU Jerums G; Cooper M E; Gilbert R E; Atkins R C
SO Medical journal of Australia, (2001 Oct 15) 175 (8) 397-9.
Journal code: 0400714. ISSN: 0025-729X.
CY Australia
DT Editorial
LA English
FS Priority Journals

EM 200112
ED Entered STN: 20011112
Last Updated on STN: 20020123
Entered Medline: 20011204

L11 ANSWER 140 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001609714 MEDLINE
DN PubMed ID: 11684568
TI Drug companies should not have the final say in the design of clinical trials.
AU Kurtzman N A
SO American journal of kidney diseases : official journal of the National Kidney Foundation, (2001 Nov) 38 (5) 1113-4.
Journal code: 8110075. ISSN: 1523-6838.
CY United States
DT Editorial
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011102
Last Updated on STN: 20020123
Entered Medline: 20011204

L11 ANSWER 141 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001562632 MEDLINE
DN PubMed ID: 11642211
TI [Current treatment of **diabetic** nephropathy in patients with type II **diabetes** mellitus. Most recent progress].
Tratamiento actual de la nefropatia **diabetica** en los pacientes con **diabetes** mellitus tipo 2. Ultimos avances.
AU de Alvaro F
CS Servicio de Nefrologia, Hospital La Paz, Madrid.
SO Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, (2001) 21 Suppl 3 76-82. Ref: 26
Journal code: 8301215. ISSN: 0211-6995.
CY Spain
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Spanish
FS Priority Journals
EM 200206
ED Entered STN: 20011022
Last Updated on STN: 20020605
Entered Medline: 20020604

L11 ANSWER 142 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001554478 MEDLINE
DN PubMed ID: 11601118
TI [Effect of **irbesartan** on the development of **diabetic** nephropathy in patients with type 2 **diabetes**].
Effekt af **irbesartan** pa udvikling af **diabetisk** nefropati hos patienter med type 2-**diabetes**.
AU Parving H H; Lehnert H; Brochner-Mortensen J; Gomis R; Andersen S; Arner P
CS Steno Diabetes Center, Gentofte.
SO Ugeskrift for laeger, (2001 Oct 1) 163 (40) 5519-24.
Journal code: 0141730. ISSN: 0041-5782.
CY Denmark

DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA Danish
FS Priority Journals
EM 200111
ED Entered STN: 20011017
Last Updated on STN: 20011105
Entered Medline: 20011101

L11 ANSWER 143 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001530000 MEDLINE
DN PubMed ID: 11576953
TI A clinical trial in type 2 **diabetic** nephropathy.
AU Lewis E J; Hunsicker L G; Rodby R A
CS Section of Nephrology, Rush-Presbyterian-St. Luke's Medical Center,
Chicago, IL, USA. (Collaborative Study Group). hfoellmer@rush.edu
SO American journal of kidney diseases : official journal of the National
Kidney Foundation, (2001 Oct) 38 (4 Suppl 1) S191-4.
Journal code: 8110075. ISSN: 1523-6838.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011001
Last Updated on STN: 20020122
Entered Medline: 20011204

L11 ANSWER 144 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001528110 MEDLINE
DN PubMed ID: 11574450
TI Angiotensin II receptor blockers and nephropathy trials.
CM Erratum in: Diabetes Care 2002 Jan;25(1):236
AU Bloomgarden Z T
SO Diabetes care, (2001 Oct) 24 (10) 1834-8.
Journal code: 7805975. ISSN: 0149-5992.
CY United States
DT Conference; Conference Article; (CONGRESSES)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011001
Last Updated on STN: 20020321
Entered Medline: 20011205

L11 ANSWER 145 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001518119 MEDLINE
DN PubMed ID: 11565519
TI The effect of **irbesartan** on the development of **diabetic** nephropathy in
patients with type 2 **diabetes**.
CM Comment in: ACP J Club. 2002 May-Jun;136(3):82-4. PubMed ID: 11985423
Comment in: N Engl J Med. 2001 Sep 20;345(12):910-2. PubMed ID: 11565525
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11870250
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873779
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873778
Comment in: Rev Cardiovasc Med. 2003 Spring;4(2):118-21. PubMed ID:

12776021

AU Parving H H; Lehnert H; Brochner-Mortensen J; Gomis R; Andersen S; Arner P
 CS Steno Diabetes Center, Copenhagen, Denmark. (Irbesartan in Patients with
 Type 2 Diabetes and Microalbuminuria Study Group).
 SO New England journal of medicine, (2001 Sep 20) 345 (12) 870-8.
 Journal code: 0255562. ISSN: 0028-4793.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200109
 ED Entered STN: 20010924
 Last Updated on STN: 20020528
 Entered Medline: 20010927

L11 ANSWER 146 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001518117 MEDLINE
 DN PubMed ID: 11565517
 TI Renoprotective effect of the angiotensin-receptor antagonist **irbesartan**
 in patients with nephropathy due to type 2 **diabetes**.
 CM Comment in: ACP J Club. 2002 May-Jun;136(3):82-4. PubMed ID: 11985424
 Comment in: N Engl J Med. 2001 Sep 20;345(12):910-2. PubMed ID: 11565525
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11870250
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873779
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873778
 Comment in: Rev Cardiovasc Med. 2003 Spring;4(2):118-21. PubMed ID:
 12776021
 AU Lewis E J; Hunsicker L G; Clarke W R; Berl T; Pohl M A; Lewis J B; Ritz E;
 Atkins R C; Rohde R; Raz I
 CS Department of Medicine, Rush-Presbyterian-St Luke's Medical Center,
 Chicago, IL 60612, USA. (Collaborative Study Group).
 SO New England journal of medicine, (2001 Sep 20) 345 (12) 851-60.
 Journal code: 0255562. ISSN: 0028-4793.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200109
 ED Entered STN: 20010924
 Last Updated on STN: 20020528
 Entered Medline: 20010927

L11 ANSWER 147 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2001508169 MEDLINE
 DN PubMed ID: 11556191
 TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also
 protects the kidneys].
 Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.
 AU Anonymous
 SO MMW Fortschritte der Medizin, (2001 Aug 9) 143 (31-32) 44.
 Journal code: 100893959. ISSN: 1438-3276.
 CY Germany: Germany, Federal Republic of
 DT News Announcement
 LA German
 FS Priority Journals

EM 200201
ED Entered STN: 20010917
Last Updated on STN: 20020125
Entered Medline: 20020103

L11 ANSWER 148 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001462980 MEDLINE
DN PubMed ID: 11508272
TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in a model of **diabetes** and hypertension.
AU Bonnet F; Cooper M E; Kawachi H; Allen T J; Boner G; Cao Z
CS Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia.
SO Diabetologia, (2001 Jul) 44 (7) 874-7.
Journal code: 0006777. ISSN: 0012-186X.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20010820
Last Updated on STN: 20020124
Entered Medline: 20020102

L11 ANSWER 149 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001451920 MEDLINE
DN PubMed ID: 11498657
TI New stuff about the **diabetic** kidney.
AU Townsend R R
CS Hypertension Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
SO Journal of clinical hypertension (Greenwich, Conn.), (2001 Jul-Aug) 3 (4) 255.
Journal code: 100888554. ISSN: 1524-6175.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20010813
Last Updated on STN: 20011015
Entered Medline: 20011011

L11 ANSWER 150 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001440495 MEDLINE
DN PubMed ID: 11461726
TI Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
CM Comment in: Int J Cardiol. 2002 Dec;86(2-3):325-6. PubMed ID: 12419573
AU Coats A J
SO International journal of cardiology, (2001 Jul) 79 (2-3) 99-102. Ref: 16
Journal code: 8200291. ISSN: 0167-5273.
CY Ireland
DT Editorial
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200109

ED Entered STN: 20010813
Last Updated on STN: 20030313
Entered Medline: 20010927

L11 ANSWER 151 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001411210 MEDLINE
DN PubMed ID: 11460392
TI [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
Meilenstein-Studien uberzeugen: Sartane wirken nephroprotektiv. Evidenter geht's nicht.
AU Bold K O
SO MMW Fortschritte der Medizin, (2001 May 31) 143 (22) 12-3.
Journal code: 100893959. ISSN: 1438-3276.
CY Germany: Germany, Federal Republic of
DT News Announcement
LA German
FS Priority Journals
EM 200108
ED Entered STN: 20010903
Last Updated on STN: 20010903
Entered Medline: 20010830

L11 ANSWER 152 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001406827 MEDLINE
DN PubMed ID: 11427096
TI Angiotensin II subtype 1 receptor blockers and renal function.
AU Toto R
CS Patient-Oriented Research in Nephrology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8856, USA..
robert.toto@utsouthwestern.edu
SO Archives of internal medicine, (2001 Jun 25) 161 (12) 1492-9. Ref: 78
Journal code: 0372440. ISSN: 0003-9926.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200107
ED Entered STN: 20010723
Last Updated on STN: 20010723
Entered Medline: 20010719

L11 ANSWER 153 OF 171 MEDLINE on STN

Full Citing
Text References

AN 2001398377 MEDLINE
DN PubMed ID: 11450162
TI [Angiotensin receptor blockers--significance for the therapy of hypertension].
Angiotensin-Rezeptor-Blocker--Bedeutung fur die Hochdrucktherapie.
AU Magometschnigg D
CS Institut fur Hypertoniker, Kinderspitalgasse 10/15-17, A-1090 Wien..
hypertonie@eunet.at
SO Wiener medizinische Wochenschrift (1946), (2001) 151 (7-8) 153-6. Ref: 55
Journal code: 8708475. ISSN: 0043-5341.
CY Austria
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA German
 FS Priority Journals
 EM 200108
 ED Entered STN: 20010827
 Last Updated on STN: 20010827
 Entered Medline: 20010823

L11 ANSWER 154 OF 171 MEDLINE on STN

Full Text Citing References

AN 2001254660 MEDLINE
 DN PubMed ID: 11352773
 TI Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in **diabetic** spontaneously hypertensive rats.
 AU Cao Z; Bonnet F; Davis B; Allen T J; Cooper M E
 CS Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West 3081, Victoria, Australia..
cao@austin.unimelb.edu.au
 SO Clinical science (London, England : 1979), (2001 Jun) 100 (6) 591-9.
 Journal code: 7905731. ISSN: 0143-5221.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200107
 ED Entered STN: 20010709
 Last Updated on STN: 20010709
 Entered Medline: 20010705

L11 ANSWER 155 OF 171 MEDLINE on STN

Full Text Citing References

AN 2001150705 MEDLINE
 DN PubMed ID: 11104169
 TI End-stage renal failure after **irbesartan** prescription in a **diabetic** patient with previously stable chronic renal insufficiency.
 AU Descombes E; Fellay G
 CS Department of Internal Medicine, Hopital Cantonal, Fribourg, Switzerland..
descombese@hopcantfr.ch
 SO Renal failure, (2000 Nov) 22 (6) 815-21.
 Journal code: 8701128. ISSN: 0886-022X.
 CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200103
 ED Entered STN: 20010404
 Last Updated on STN: 20010404
 Entered Medline: 20010315

L11 ANSWER 156 OF 171 MEDLINE on STN

Full Text Citing References

AN 2001136549 MEDLINE
 DN PubMed ID: 11110232
 TI A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of **irbesartan** in patients aged > or = 65 years with mild to moderate hypertension.
 AU Lacourciere Y
 CS Hypertension Unit, Centre Hospitalier Universitaire Laval, Quebec City, Quebec, Canada.
 SO Clinical therapeutics, (2000 Oct) 22 (10) 1213-24.
 Journal code: 7706726. ISSN: 0149-2918.

CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200103
 ED Entered STN: 20010404
 Last Updated on STN: 20010404
 Entered Medline: 20010301

L11 ANSWER 157 OF 171 MEDLINE on STN

Full Text Citing References

AN 2001096652 MEDLINE
 DN PubMed ID: 11129125
 TI Lercanidipine: a review of its use in hypertension.
 AU McClellan K J; Jarvis B
 CS Adis International Limited, Auckland, New Zealand.. demail@adis.co.nz
 SO Drugs, (2000 Nov) 60 (5) 1123-40. Ref: 59
 Journal code: 7600076. ISSN: 0012-6667.
 CY New Zealand
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200102
 ED Entered STN: 20010322
 Last Updated on STN: 20010322
 Entered Medline: 20010201

L11 ANSWER 158 OF 171 MEDLINE on STN

Full Text Citing References

AN 2000438371 MEDLINE
 DN PubMed ID: 10854085
 TI Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
 AU Israili Z H
 CS Emory University School of Medicine, Atlanta, GA 30303, USA.
 SO Journal of human hypertension, (2000 Apr) 14 Suppl 1 S73-86. Ref: 174
 Journal code: 8811625. ISSN: 0950-9240.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English
 FS Priority Journals
 EM 200009
 ED Entered STN: 20000928
 Last Updated on STN: 20000928
 Entered Medline: 20000915

L11 ANSWER 159 OF 171 MEDLINE on STN

Full Text Citing References

AN 2000438370 MEDLINE
 DN PubMed ID: 10854084
 TI Angiotensin II receptor antagonists in arterial hypertension.
 AU Hernandez-Hernandez R; Velasco M; Armas-Hernandez M J; Armas-Padilla M C
 CS Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela.

SO Journal of human hypertension, (2000 Apr) 14 Suppl 1 S69-72. Ref: 34
 Journal code: 8811625. ISSN: 0950-9240.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200009
 ED Entered STN: 20000928
 Last Updated on STN: 20000928
 Entered Medline: 20000915

L11 ANSWER 160 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2000193846 MEDLINE
 DN PubMed ID: 10727543
 TI The **Irbesartan** type II **diabetic** nephropathy trial: study design and
 baseline patient characteristics. For the Collaborative Study Group.
 AU Rodby R A; Rohde R D; Clarke W R; Hunsicker L G; Anzalone D A; Atkins R C;
 Ritz E; Lewis E J
 CS The Section of Nephrology, Department of Medicine, Rush Medical College,
 Chicago, IL, USA.
 SO Nephrology, dialysis, transplantation : official publication of the
 European Dialysis and Transplant Association - European Renal Association,
 (2000 Apr) 15 (4) 487-97.
 Journal code: 8706402. ISSN: 0931-0509.
 CY ENGLAND: United Kingdom
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (MULTICENTER STUDY)
 (RANDOMIZED CONTROLLED TRIAL)
 LA English
 FS Priority Journals
 EM 200005
 ED Entered STN: 20000525
 Last Updated on STN: 20000525
 Entered Medline: 20000517

L11 ANSWER 161 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2000190664 MEDLINE
 DN PubMed ID: 10726465
 TI [Organ protection in hypertensive type 2 **diabetic** patients. Double
 chance with AT1 blockers].
 Organprotektion bei hypertensiven Typ-2-**Diabetikern**. Zweifache Chance
 mit AT1-Blockern.
 AU Anonymous
 SO MMW Fortschritte der Medizin, (2000 Jan 20) 142 (3) 58-9.
 Journal code: 100893959. ISSN: 1438-3276.
 CY GERMANY: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200004
 ED Entered STN: 20000421
 Last Updated on STN: 20000421
 Entered Medline: 20000411

L11 ANSWER 162 OF 171 MEDLINE on STN

Full Text	Citing References
--------------	----------------------

AN 2000094526 MEDLINE

DN PubMed ID: 10630830
 TI Candesartan cilexetil: an angiotensin II receptor blocker.
 AU Stoukides C A; McVoy H J; Kaul A F
 CS Medical Outcomes Management, Inc., Foxborough, MA 02035, USA.
 SO Annals of pharmacotherapy, (1999 Dec) 33 (12) 1287-98. Ref: 72
 Journal code: 9203131. ISSN: 1060-0280.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200002
 ED Entered STN: 20000209
 Last Updated on STN: 20030313
 Entered Medline: 20000203

L11 ANSWER 163 OF 171 MEDLINE on STN

Full Text Citing References

AN 2000081217 MEDLINE
 DN PubMed ID: 10614150
 TI [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
 Ventajas antihipertensivas del antagonismo de los receptores AT1 de la
 angiotensina II.
 AU Coca A; Giner V
 CS Departamento de Medicina, Instituto de Investigaciones Biomedicas August
 Pi Sunyer (IDIBAPS), Hospital Clinico, Universidad de Barcelona.
 SO Revista espanola de cardiologia, (1999) 52 Suppl 3 53-8. Ref: 47
 Journal code: 0404277. ISSN: 0300-8932.
 CY Spain
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Spanish
 FS Priority Journals
 EM 200001
 ED Entered STN: 20000131
 Last Updated on STN: 20000131
 Entered Medline: 20000114

L11 ANSWER 164 OF 171 MEDLINE on STN

Full Text Citing References

AN 2000007311 MEDLINE
 DN PubMed ID: 10541298
 TI The paradox of the low-renin state in **diabetic** nephropathy.
 AU Price D A; Porter L E; Gordon M; Fisher N D; De'Oliveira J M; Laffel L M;
 Passan D R; Williams G H; Hollenberg N K
 CS Department of Medicine, Harvard Medical School and Brigham and Women's
 Hospital, Boston, Massachusetts 02115, USA.. daprice@bics.bwh.harvard.edu
 NC M01 RR-026376 (NCRR)
 P01AC00059916
 T32 HL-07609 (NHLBI)
 +
 SO Journal of the American Society of Nephrology : JASN, (1999 Nov) 10 (11)
 2382-91.
 Journal code: 9013836. ISSN: 1046-6673.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Space Life Sciences
 EM 199911
 ED Entered STN: 20000111
 Last Updated on STN: 20000111

Entered Medline: 19991118

L11 ANSWER 165 OF 171 MEDLINE on STN

Full Text Citing References

AN 1999372258 MEDLINE
 DN PubMed ID: 10443311
 TI [Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?].
 Les antagonistes des recepteurs AT1 de l'angiotensine II sont-ils nephroprotecteurs?..
 AU Deray G
 CS Service de nephrologie, Groupe hospitalier La Pitie-La Salpetriere, Paris.
 SO Archives des maladies du coeur et des vaisseaux, (1999 Jul) 92 (7) 903-7.
 Ref: 26
 Journal code: 0406011. ISSN: 0003-9683.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA French
 FS Priority Journals
 EM 199909
 ED Entered STN: 19990925
 Last Updated on STN: 19990925
 Entered Medline: 19990909

L11 ANSWER 166 OF 171 MEDLINE on STN

Full Text Citing References

AN 1999216066 MEDLINE
 DN PubMed ID: 10201883
 TI Comparative antihypertensive effects of angiotensin II receptor antagonists.
 AU Burnier M; Brunner H R
 CS Division of Hypertension and Vascular Medicine, Lausanne, Switzerland..
 Michel.Burnier@chuv.hospvd.ch
 SO Journal of the American Society of Nephrology : JASN, (1999 Apr) 10 Suppl 12 S278-82. Ref: 40
 Journal code: 9013836. ISSN: 1046-6673.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199909
 ED Entered STN: 19990921
 Last Updated on STN: 19990921
 Entered Medline: 19990909

L11 ANSWER 167 OF 171 MEDLINE on STN

Full Text Citing References

AN 1999070669 MEDLINE
 DN PubMed ID: 9855027
 TI Optimizing antihypertensive therapy in patients with **diabetic** nephropathy.
 AU Ritz E; Rychlik I; Miltenberger-Miltenyi G
 CS Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1998 Sep) 16 (7) S17-22. Ref: 54
 Journal code: 8501422. ISSN: 0952-1178.
 CY ENGLAND: United Kingdom

DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199902
ED Entered STN: 19990311
Last Updated on STN: 19990311
Entered Medline: 19990222

L11 ANSWER 168 OF 171 MEDLINE on STN

Full Text Citing References

AN 1998193697 MEDLINE
DN PubMed ID: 9532518
TI Clinical overview of **irbesartan**: expanding the therapeutic window in hypertension.
AU Man in't Veld A J
CS Department of Internal Medicine, Academisch Ziekenhuis Dijkzigt, Rotterdam, The Netherlands.
SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1997 Dec) 15 (7) S27-33. Journal code: 8501422. ISSN: 0952-1178.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(META-ANALYSIS)
LA English
FS Priority Journals
EM 199805
ED Entered STN: 19980609
Last Updated on STN: 19980609
Entered Medline: 19980528

L11 ANSWER 169 OF 171 MEDLINE on STN

Full Text Citing References

AN 1998193694 MEDLINE
DN PubMed ID: 9532515
TI Non-insulin-dependent **diabetes** mellitus, nephropathy, and the renin system.
AU Hollenberg N K
CS Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1997 Dec) 15 (7) S7-13. Ref: 52
Journal code: 8501422. ISSN: 0952-1178.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199805
ED Entered STN: 19980609
Last Updated on STN: 19980609
Entered Medline: 19980528

L11 ANSWER 170 OF 171 MEDLINE on STN

Full Text Citing References

AN 1998099615 MEDLINE
DN PubMed ID: 9438777
TI Renoprotection and renin-angiotensin system blockade in **diabetes** mellitus.

AU Ruilope L M
 CS Universidad Complutense, Chief Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.
 SO American journal of hypertension : journal of the American Society of Hypertension, (1997 Dec) 10 (12 Pt 2) 325S-331S. Ref: 68
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT (CLINICAL TRIAL)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199802
 ED Entered STN: 19980224
 Last Updated on STN: 20000303
 Entered Medline: 19980212

L11 ANSWER 171 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 1998071355 MEDLINE
 DN PubMed ID: 9407464
 TI **Irbesartan** lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent **diabetes** mellitus.
 AU O'Donnell M P; Crary G S; Oda H; Kasiske B L; Powell J R; Keane W F
 CS Department of Medicine, Hennepin County Medical Center, Minneapolis, USA.
 SO Kidney international. Supplement, (1997 Dec) 63 S218-20.
 Journal code: 7508622. ISSN: 0098-6577.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199802
 ED Entered STN: 19980217
 Last Updated on STN: 19980217
 Entered Medline: 19980205

=> d an ti au so kwic 148

L11 ANSWER 148 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2001462980 MEDLINE
 TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in a model of **diabetes** and hypertension.
 AU Bonnet F; Cooper M E; Kawachi H; Allen T J; Boner G; Cao Z
 SO Diabetologia, (2001 Jul) 44 (7) 874-7.
 Journal code: 0006777. ISSN: 0012-186X.
 TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in a model of **diabetes** and hypertension.
 AB . . . key role in the function of the glomerular filtration barrier and the development of proteinuria but its status in long-term **diabetes** is still not understood. We studied the expression of nephrin in a hypertensive model of **diabetic** nephropathy and investigated the potential influence of angiotensin II blockade on nephrin gene and protein expression. METHODS: Streptozotocin-**diabetic** spontaneously hypertensive rats were given either no treatment or the angiotensin II antagonist, **irbesartan**, at a dose of 15 mg/kg per day by gavage for 32 weeks. Non-**diabetic** spontaneously hypertensive rats were used as a control group. Real time RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of nephrin. RESULTS: **Diabetic**

spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats. **Irbesartan** treatment prevented the development of albuminuria and completely abrogated the down regulation of nephrin in **diabetic** rats.

CONCLUSION/INTERPRETATION: Long-term **diabetes** in spontaneously hypertensive rats is associated with a reduction in both gene and protein expression of nephrin within the kidney.. . .

CT Check Tags: Male; Support, Non-U.S. Gov't

Albuminuria: PC, prevention & control

Analysis of Variance

Animals

*Biphenyl Compounds: PD, pharmacology

Diabetes Mellitus, Experimental: DT, drug therapy

***Diabetes Mellitus, Experimental: PP, physiopathology**

Disease Models, Animal

Gene Expression Regulation: DE, drug effects

*Hypertension: DT, drug therapy

Oligonucleotide Probes

*Proteins:.. . .

RN 138402-11-6 (**irbesartan**)

=> d an ti au so kwic 147

L11 ANSWER 147 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2001508169 MEDLINE

TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also protects the kidneys].

Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.

AU Anonymous

SO MMW Fortschritte der Medizin, (2001 Aug 9) 143 (31-32) 44.

Journal code: 100893959. ISSN: 1438-3276.

TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also protects the kidneys].

Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.

CT

AE, adverse effects

*Antihypertensive Agents: TU, therapeutic use

Biphenyl Compounds: AE, adverse effects

*Biphenyl Compounds: TU, therapeutic use

Clinical Trials

***Diabetes Mellitus, Type II: DT, drug therapy**

***Diabetic Nephropathies: PC, prevention & control**

*Hypertension: DT, drug therapy

*Receptors, Angiotensin: AI, antagonists & inhibitors

Tetrazoles: AE, adverse effects

*Tetrazoles:.. . .

RN 138402-11-6 (**irbesartan**)

=> d an ti au so kwic 139

L11 ANSWER 139 OF 171 MEDLINE on STN

Full Text	Citing References
-----------	-------------------

AN 2001648685 MEDLINE

TI Renal protection by angiotensin II receptor antagonists in patients with type 2 **diabetes**.

AU Jerums G; Cooper M E; Gilbert R E; Atkins R C

SO Medical journal of Australia, (2001 Oct 15) 175 (8) 397-9.

Journal code: 0400714. ISSN: 0025-729X.

TI Renal protection by angiotensin II receptor antagonists in patients with

type 2 **diabetes**.

CT Check Tags: Female; Male

*Angiotensin II

*Biphenyl Compounds: AD, administration & dosage
Clinical Trials

Diabetes Mellitus, Type 2: CO, complications

Diabetic Nephropathies: ET, etiology

***Diabetic Nephropathies: PC, prevention & control**
Humans

Hypertension, Renal: ET, etiology

*Hypertension, Renal: PC, prevention & control

Kidney: DE, drug effects

RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); 138402-11-6
(**irbesartan**)

=> d an ti au so kwic 133

L11 ANSWER 133 OF 171 MEDLINE on STN

☐ Full
Text ☐ Citings
References

AN 2002051143 MEDLINE

TI The protective effect of blocking angiotensin in both type I and type II
diabetics with nephropathy.

AU Beevers D G; Lip G Y

SO Journal of human hypertension, (2001 Dec) 15 (12) 837-9. Ref: 14

Journal code: 8811625. ISSN: 0950-9240.

TI The protective effect of blocking angiotensin in both type I and type II
diabetics with nephropathy.

CT . . .

BI, biosynthesis

*Angiotensin II: DE, drug effects

*Angiotensin-Converting Enzyme Inhibitors: AD, administration & dosage

Biphenyl Compounds: AD, administration & dosage

Diabetes Mellitus, Type I: CO, complications

Diabetes Mellitus, Type II: CO, complications

Diabetic Nephropathies: DT, drug therapy

***Diabetic Nephropathies: PC, prevention & control**

Losartan: AD, administration & dosage

Middle Aged

Primary Prevention: MT, methods

Prognosis

Randomized Controlled Trials

RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); 138402-11-6
(**irbesartan**); 9041-90-1 (Angiotensin I)

=> d an ti au so kwic 129

L11 ANSWER 129 OF 171 MEDLINE on STN

☐ Full
Text ☐ Citings
References

AN 2002098783 MEDLINE

TI Preventing nephropathy in patients with type 2 **diabetes**.

AU Anonymous

SO Managed care interface, (2002 Jan) 15 (1) 72-5.

Journal code: 9715194. ISSN: 1096-5645.

TI Preventing nephropathy in patients with type 2 **diabetes**.

CT Check Tags: Human

*Antihypertensive Agents: AD, administration & dosage

Biphenyl Compounds: AD, administration & dosage

*Diabetes Mellitus, Type II: CO, complications
 Diabetic Nephropathies: CO, complications
 *Diabetic Nephropathies: PC, prevention & control
 *Disease Management
 Hypertension: CO, complications
 *Hypertension: DT, drug therapy
 Kidney Failure, Chronic: CO, complications
 Kidney. . .

RN 114798-26-4 (Losartan); 138402-11-6 (irbesartan)

=> d an ti au so kwic 122

L11 ANSWER 122 OF 171 MEDLINE on STN

Full Citing
 Text References

AN 2002146932 MEDLINE

TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes** mellitus.

AU Asmar R

SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 Suppl 2 S8-11.

Journal code: 100971636. ISSN: 1470-3203.

TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes** mellitus.

AB . . . wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent **diabetes** mellitus. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central. . . peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 **diabetes** mellitus, were randomised to once daily treatment with either **telmisartan** 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a. . . were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with **telmisartan** significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s, p=0.013), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of the this study show that **telmisartan** is effective in reducing arterial stiffness in hypertensive patients with Type 2 **diabetes** mellitus, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects in the patient group.

CT . . .

Aged

*Angiotensin-Converting Enzyme Inhibitors: TU, therapeutic use
 *Benzimidazoles: TU, therapeutic use
 *Benzoates: TU, therapeutic use
 Blood Pressure: DE, drug effects
 *Diabetes Mellitus, Type II: CO, complications
 Double-Blind Method
 *Hypertension: DT, drug therapy
 Middle Aged
 Prospective Studies
 Pulsatile Flow: DE, drug effects

RN 144701-48-4 (telmisartan)

=>

